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1 Introduction 
 
1.1 Stem cells 
 
Stem cells are defined as cells with the ability for self-renewal and differentiation into 
other cell types (Weissmann et al., 2000; Cai et al., 2004). This can be achieved by 
symmetric cell division (proliferation) and asymmetric cell division (differentiation) 
(Martin-Rendon and Watt, 2003). Regarding the potency of the cells to develop into other 
cell types they are classified as totipotent, multipotent and pluripotent. Totipotent cells 
can differentiate into all cell types of an organism and originate from a fertilized oocyte 
up to its forth cell division.  A pluripotent or embryonic stem cell is derived from the inner 
mass of a blastocyst and can differentiate into cells of all three germ layers: endoderm, 
ectoderm and mesoderm (Loebel et al., 2003). Multipotent, adult stem cells or progenitor 
cells can be found in different adult tissues. Their differentiation is limited to the cells of 
the tissue they originate from. (Körbling and Estrov, 2003). 
 
1.1.1 Neural progenitor cells and neurogenesis 
 
During embryogenesis, the neural plate is developed out of the ectoderm of the 
blastocyst, which later on forms the neural tube. Forebrain and midbrain arise from the 
front part of the neural tube, whereas the back part creates the hindbrain and the spinal 
cord. The differentiation of neural progenitor cells (NPC) into neurons or glia cells is 
initiated by signals from the mesoderm (Kandel et al., 2000). 
Neural progenitor cells or neural stem cells can be found in different brain regions, such 
as the hypothalamus, the dentate gyrus of the hippocampus and the forebrain, the 
structure of the subventricular zones of the lateral ventricle of the olfactory bulb and the 
subgranular zone of the dentate gyrus (Temple and Alvarez-Byulla, 1999). NPC can be 
used for proliferation and differentiation studies and can be obtained either from 
embryonic stem cells (Zhang et al., 2001; Schuldiner et al., 2001; Kim et al., 2007) or 
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directly isolated from fetal or adult tissue (Ling et al., 1998; Akiyama et al, 2001; 
Arsenijevic et al., 2001).  
Whether these cells give rise to neurons or glia cells is dependent on the stage of 
development, since the asymmetric cell division around E13 leads in mice to an increase 
of neurons, whereas asymmetric cell divisions at stage 18 pc (post coitum) and early 
postnatal stages form more glial cells (Hirabayashi and Gotoh, 2005). 
To cultivate NPCs in vitro, either mitogens or immortalization via the transduction of an 
immortalized oncogene are used. This promotes standardized culturing conditions. 
Primary cell lines are limited regarding their availability (Palmer et al., 2001) whereas 
immortalized cells might display different behavior due to the presence of the oncogene, 
but they obtain a stable genotype and phenotype (Dang et al., 1999; Kim 2004).  
Several immortalized cell lines have been published: V-myc propagated NPC lines include 
C17.2, derived from mouse cerebellum (Ryder et al., 1990), H6, derived from human 15-
week-old telencephalon (Flax et al., 1998), HNSC.100, derived from human 10-week-old 
forebrain (Villa et al., 2002), Mes2, derived from human 8-week-old VM (Lotharius et al., 
2002). In this study, a human neural progenitor cell line ReNcell VM, derived from the 
ventral midbrain of a 10-week-old fetus, has been used. Detailed information about this 
cell line will be given in paragraph 1.4.  
To obtain a proliferating state, the addition of growth factors to the cultivation medium is 
required, the most common ones are the epidermal growth factor (EGF) or the fibroblast 
growth factor (FGF)-2 (Tropepe et al., 1999). The withdrawal of growth factors induces 
differentiation into a region-appropriate progeny (Potter et al., 1999). 
 
 
1.2 Wnt signaling 
 
Wnt signaling pathways are involved in various cellular processes such as proliferation, 
cell death, cell polarity, morphogenic movements or self-renewal (Moon et al., 2004). Up 
to now, three different intracellular pathways have been known where a Wnt ligand binds 
to a Fzd receptor.  
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1. Wnt/β-catenin pathway (“canonical” pathway) 
2. PCP (planar cell polarity) pathway 
3. Wnt/Ca2+ pathway  
 
1.2.1 Wnt/β-catenin pathway 
 
The Wnt/β-catenin pathway is one of the best described pathways. It is mainly 
characterized by β-catenin and its degradation (inactive state) or accumulation (active 
state). β-catenin is a constitutively expressed protein which is involved in cell adhesion. It 
connects cadherin cell adhesion molecules to the cytoskeleton (Aberle et al., 1996). 
 
 
Figure 1: Overview of Wnt/β-catenin signaling 
A) In the absence of Wnt, cytoplasmic β-catenin forms a complex with Axin, APC, GSK3 and CK1, 
and is phosphorylated by CK1 (blue) and subsequently by GSK3 (yellow). Phosphorylated β-
catenin is recognized by the E3 ubiquitin ligase β-Trcp, which targets β-catenin for proteosomal 
degradation. Wnt target genes are repressed by TCF-TLE/Groucho and histone deacetylases 
(HDAC). B) In the presence of a Wnt ligand, a receptor complex forms between Fzd and LRP5/6. 
Dvl recruitment by Fzd leads to LRP5/6 phosphorylation and Axin recruitment. This disrupts Axin-
mediated phosphorylation/degradation of β-catenin, allowing β-catenin to accumulate in the 
nucleus where it serves as a co-activator for TCF to activate Wnt responsive genes. (MacDonald et 
al., 2009) 
 
Inactive state 
In an inactive state, β-catenin is phosphorylated by a degradation-complex and 
subsequently degraded in the cytosol. The degradation complex consists of GSK-3β, APC 
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and, Axin and CK1. GSK-3β and CK1 phosphorylate β-catenin at its amino-terminal region, 
at which CK1α is responsible for phosphorylation at Ser45 and subsequently GSK-3β for 
phosphorylation at threonine 41, serine 37 and serine 33 (Kimelman and Xu, 2006). The 
phosphorylation of Serine 37 and 33 forms a binding site for β-TrCP (transducin repeat-
containing protein), which is an E3 ubiquitin ligase unit. This enzyme ubiquitinates β-
catenin, which is then degraded by proteosomes in the cytosol (Fig. 1a) (He et al., 2004). 
Beside GSK-3β, Axin and APC are also crucial for the degradation process. Both proteins 
are also phosphorylated by GSK-3β and CK1, which causes an increased interaction of 
Axin and APC with β-catenin, subsequently resulting in an enhanced 
phosphorylation/degradation of β-catenin (Kimelman and Xu, 2006; Huang and He, 2008).  
 
Active State 
For activation, two receptor families are required: frizzled seven-pass transmembrane 
receptors (Fzd) (Logan and Nusse 2004) and LDL receptor related proteins 5 and 6 (LRP5 
and 6) (He et al, 2004). The family of 10 Fzd receptors are composed of seven 
transmembrane domains and an extracellular conserved cystein rich domaine, which is 
crucial for Wnt ligand binding.  LRP6 is not only essential for activation of Wnt/β-Catenin 
signaling, but can also inhibit the non-canonical pathways in vivo, whereas the 
mechanism has not been well described yet. Bryja et al. (2009) described a competing 
mechanism for Wnt ligands, while Tahinci and co-workers (2007) elucidated the effect but 
not the mechanism. Fzd receptors play a role in both signaling pathways, canonical and 
non-canonical ones (Medina et al., 2000). 
In addition to these two main receptor families, other receptors have been described. 
Ryk, an atypical tyrosine kinase (Hsieh et al., 1999) and Ror2 are not necessary for Wnt/β-
catenin signaling, but they can inhibit the pathway (van Amerogen et al., 2008) by binding 
the Wnt inhibitory factor (WIF) or activating c-Jun N-terminal kinase (JNK), respectively.  
Upon binding of a Wnt ligand to the receptors, LRP6 is phosphorylated by GSK-3β and 
CK1α (Tamai et al, 2004). Cytoplasmic Dishevelled (Dvl) is recruited to the membrane and 
interacts with Fzd, which is not well understood yet but could be triggered by the 
activation of heterotrimeric G-proteins (Cadigan and Liu, 2006). Axin now binds to the 
dual phosphorylated PPPSPxS motifs of LRP6 (Davidson et al., 2005; Tamai et al., 2004; 
Zeng et al., 2005), resulting in the disruption of the degradation complex (Fig. 1b). In 
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addition, the phosphorylated LRP6 cytoplasmic domain or individual phospho-PPPSPxS 
peptides can directly inhibit GSK-3β phosphorylation of β-catenin in vitro (Cselenyi et al., 
2008; Piao et al., 2008; Wu et al., 2009). 
 
β-catenin is now not longer degraded but translocated in the nucleus. This mechanism is 
poorly understood (Henderson and Fagotto, 2002; Stadeli et al., 2006). β-catenin 
possesses no nuclear localization signal, which would trigger the nuclear localization 
(Henderson and Fagotto, 2002). Wu et al. (2008) described that the β-catenin 
accumulation induced by Wnt-ligand binding is not effectual enough for the translocation 
process. They suggested that Wnt activation of Rac1 GTPase is required as well.  
In the nucleus, β-Catenin binds to the TCF (T-cell factor) /LEF (lymphoid enhancer binding 
factor) family of DNA-bound transcription factors (Fig. 1b) (Arce et al., 2006; Hoppler and 
Kavanagh, 2007). It replaces the repressor Groucho, promotes histone deacetylation and 
chromatin compaction (Daniels and Weis, 2005) and recruits co-activators such as CBP 
(CREB binding protein), BCL (B-cell lymphoma 9) and Pygo (Pygopus) (Klaus und 
Birchmeier, 2008). By this process, the transcription of Wnt-target genes is activated, 
whereas Wnt target genes are divers (Vlad et al., 2008) and cell- and context dependent 
(Logan and Nusse, 2004). For an updated list, see the Wnt homepage 
http://www.stanford.edu/~rnusse/wntwindow.html. It is noteworthy that many genes of 
Wnt signaling components are regulated by TCF/β-catenin (Chamorro et al., 2005; 
Kazanskaya et al., 2004; Khan et al., 2007; Logan and Nusse, 2004). 
 
1.2.2 Non-canonical Wnt pathways 
 
Non-canonical pathways require the binding of a Wnt ligand to a Fzd receptor but are 
independent of β-catenin. They are involved in planar cell polarity (PCP), gastrulation, 
migration, convergent extension and transcription (Schambony and Wedlich, 2007). Two 
β-catenin independent pathways are described, namely the Wnt/PCP and the Wnt/Ca2+ 
pathway. 
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Figure 2: Wnt Pathways. The extracellular signaling molecule WNT activates three pathways: (1) 
Early cell fate decisions are controlled via the canonical pathway (middle): it comprises the 
regulation of gene expression by inducing β-catenin-mediated transcriptional  activation. 
Interaction of WNT with the transmembrane receptor frizzled (FZD) activates dishevelled (DVL), 
which induces the disassembly of a complex consisting of Axin, adenomatosis polysis coli (APC), 
glycogen synthase kinase 3β (GSK3β) and β-catenin. In non-stimulated cells, GSK3β 
phosphorylates β-catenin, thereby triggering its degradation. Activitation of the pathway 
effectively increases the levels of β-catenin in the cyctoplasm, which is then translocated to the 
nucleus. Here it forms the β-catenin-T-cell specific transcription factor complex that activates the 
transcription of target genes. (2) In the planar cell polarity pathway (left), FZD functions through 
G-proteins to activate DVL, which thereupon signals to Rho GTPases (Rho or Rac or both). 
Activated Ras signals through the c-Jun amino (N)-terminal kinase (JNK). Activation of Rho-
GTPases induces changes in the cytoskeleton. In neurons, this pathway is involved in dendritic 
arborization. (3) In the WNT/calcium pathway (right), activation of DVL activates protein kinase C 
(PKC) and induces the release of intracellular calcium, which activates a calcium/calmodulin-
dependent protein kinase II (CaMKII). Klipp and Liebermeister BMC Neuroscience 2006 7 
 
Wnt/PCP pathway 
The Wnt/PCP pathway is responsible for polarization of epithelial cells, e.g. during 
gastrulation or hair orientation (Zeeman et al., 2003). The binding of a Wnt ligand to Fzd 
leads, via Dvl, to the activation of JNK and of small GTPases (heterotrimeric G proteins) 
Rac (Ras-related C3 botulinum toxine substrate) and RhoA (Ras homologous A) 
(Wallingford and Habas, 2005). Rac activation is followed by a signaling cascade which 
subsequently activates DAAM1 and RhoGTPase (Habas et al., 2001) which in turn 
activates ROCK (Rho-associated kinase) (Fig. 2.2). This part of Wnt/PCP signaling is 
associated to focal adhesions and the rearrangement of the actin cytoskeleton (Ridley 
and Hall, 1992; Leung et al., 1995). The Rac branch can activate JNK independently of 
1 2 3 
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DAAM1 (Disheveled-associated activator of morphogenesis 1) which influences 
cytoskeleton dynamics (Wallingford and Habas, 2005). Known ligands for activation of this 
pathway are Wnt 4, 5a and 11. 
 
Wnt/Ca
2+
 pathway 
The overexpression of Wnt 5a or 11 has been shown to increase the intracellular Ca-
concentration without influencing the expression of β-catenin (Slusarski et al., 1997b), 
first indicating that there might be a signaling pathway that includes the binding of a Wnt 
ligand to a Fzd receptor, but without any involvement of β-catenin. When a Wnt ligand 
binds to Fzd and heterodimeric G-proteins, diacylglyerol and IP3 are generated and later 
on calcium fluxes (Sheldahl et al., 2003). The key enzyme in the pathway is CamKII 
(calcium/calmodulin-dependent kinase), which is activated by calcium ions as well as PKC 
(protein kinase C) (Kuhl et al., 2000). Active CamKII can control the transcription Factor 
NFAT (nuclear factor of activated T-cells), which is, similar to β-catenin, translocated to 
the nucleus where it regulates the transcription of target genes (Fig. 2.3) (Dejmek et al., 
2006). 
 
1.2.3 GSK-3 
 
GSK-3 is, together with β-catenin, the key player of the Wnt/β-catenin pathway. It was 
originally identified as a protein kinase which is involved in the glycogen metabolism, 
which was soon followed by the investigation of its importance for Wnt signaling. GSK-3 is 
encoded in mammals by two genes, GSK-3α and GSK-β. They share an almost complete 
sequence identity of their protein kinase domains, but differ in their N- and C-terminal 
regions (Woodgett, 1990). Two different splicing variants of GSK-3β are described in 
humans and rodents, GSK-3β1 and GSK-3β2. GSK-3β1 is expressed ubiquitously, whereas 
GSK-3β2 is expressed specifically in the nervous system, especially during development 
(Mukai et al., 2002). Recently, a role for this splicing variant during neuronal 
morphogenesis has been described (Wood-Kaczmar et al., 2009; Castano et al., 2010). In 
addition to β-catenin a plethora of substrates for GSK-3β are described, including proteins 
which are involved in metabolism and signaling, structural proteins or transcription 
factors. GSK-3 is regulated by an inactivation-phosphorylation, GSK-3α at Ser21 (Serin21), 
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GSK-3β at Ser9. The activation phosphorylation is within the T-Loop at Y279/216 (GSK-3α 
and β, respectively) (Hughes et al., 1993).  
 
 
Figure 3: Potential sites for inhibition of glycogen synthase kinase 3 (GSK-3). Most kinase 
inhibitors act by competition with either ATP or metal-binding sites that are directly involved in 
the catalytic process. However, small-molecular-weight compounds might regulate GSK-3 activity 
by inhibiting the protein–protein interactions that are necessary for the binding of substrate [the 
primed phosphorylated serine binding area and the docking protein (Axin and presenilin)], by 
modulating the Tyr216 (GSK-3b) and Tyr279 (GSK-3a) activation sites and the Ser9 (GSK-3b) and 
Ser21 (GSK-3a) inhibition sites, and by interfering with the intracellular targeting domain of GSK-3. 
Inhibition of the interaction between the docking protein and the priming kinase might change 
the substrate specificity of GSK-3. Meijer et al, 2004  
 
GSK-3 has an important neuronal function as one of its substrate CRMP2 (collapsin 
response mediator protein2) (Cole et al., 2004; Jiang et al., 2005, Yoshimura et al., 2005). 
CRMP2 binds to microtubulins. This can be suppressed by GSK-3 via phosphorylation of 
CRMP2 resulting in increased microtubule polymerization and axonal outgrowth. Another 
neuronal target is Tau. Tau is a phosphoprotein that is associated with microtubules in 
normal mature neurons. It supports tubulin-assembling to microtubulins and promotes 
stabilization of microtubulin structures (Weingarten et al., 1975). Enhanced 
phosphorylation of Tau leads to neurofibrillary tangle precipitates, which is observed in 
Alzheimer’s disease (AD) (Maccioni et al., 2001). GSK-3 seems to play an important role in 
AD, as inhibition of GSK-3α results in decreased production of Aβ peptide from amyloid 
precursor protein (Phiel et al., 2003). GSK-3 is also of interest in schizophrenia, as the 
characteristic protein DISC1 (disrupted-in-schizophrenia 1) is regulated by GSK-3β/β-
catenin signaling (Mao et al., 2009). This protein interacts with GSK-3β and blocks its 
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activity. Mice lacking DISC1 in the dentate gyrus display schizophrenia- and depression-
like symptoms. This behavior was normalized by treatment with a GSK-3 inhibitor (Mao et 
al., 2009). Other diseases which are linked to GSK-3 are diabetes (Cohen and Goedert, 
2004), cancer or bipolar disorders (Gould, 2006). This makes it an attractive 
pharmacological target. A classic example for a GSK-3β inhibitor as a drug is lithium which 
has been used as a mood stabilizer for over 50 years (Klein and Melton, 1996). Prominent 
drugs are SB-216763 (Coghlan et al., 2000), Kenpaullone (Bain et al., 2003; Leost et al., 
2000) or 6-Bromoindirubin-3’-oxime (BIO) (Meijer et al., 2003; Polychronopoulos et al., 
2004). Most of the described GSK-3 inhibitors act via ATP-competition, whereas Lithium 
or Beryllium are Mg-competitive (Forde and Dale, 2007). For a detailed review regarding 
GSK-3, its regulation, substrates and connection to neural development see Forde and 
Dale, 2007 or Hur and Zhou, 2010. 
 
1.2.4 Wnt signaling and GSK-3 in NPC 
 
The role of Wnt signaling in hNPCs is not well described yet. β-catenin was first identified 
in the brain in 1998 (Zhang et al., 1998). From then on, a plethora of studies have 
described the roles of Wnt signaling in NPC. In general, one can say that Wnt participates 
in nearly all processes which are involved in generating a functional neuron from a neural 
stem cell, such as neural induction (Wilson et al., 2001), anterior-posterior patterning 
(Popperl et al., 1997), migration (Chenn and Walsh, 2003), axon guidance (Lu et al., 2004), 
synaptogenesis (Hall et al., 2000) and dendritogenesis (Yu et al., 2003). 
Wnts act on the developing murine CNS. The active form of β-catenin increases the 
proliferation of the neural progenitor pool, which enlarges the entire neural tube (Chenn 
and Walsh, 2003). In line with these data, it has been reported that the knock-out of β-
catenin decreases the size of different brain regions (Zechner et al., 2003). 
In isolated NPC, the stage of origin is of great importance. Murine NPCs from early stages 
(E8.5-10.5) show an increased proliferation following the canonical Wnt stimulus (Viti et 
al., 2003), whereas NPCs from later stages (E11.5-13.5) respond with an enhanced 
neuronal differentiation (Hirabayashi et al., 2004; Muroyama et al., 2004).  
 The influence of canonical Wnt signaling on dopaminergic differentiation is also of great 
interest. Different in vitro studies describe the influence of different Wnt ligands on 
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dopaminergic differentiation studies in the midbrain of mice (Castelo-Branco et al., 2003; 
Schulte et al., 2005). Wnt5a is crucial for the morphogenesis of the ventral midbrain and 
dopaminergic differentiation of NPC (Andersson et al., 2008). Recent studies describe that 
β-catenin regulates midbrain dopaminergic differentiation in vivo (Joksimovic et al., 2009; 
Tang et al., 2010). 
Several pathways beside Wnt signaling are reported to regulate proliferation or 
differentiation of neural progenitor cells: Notch (Yoon and Gaiano, 2005), SHH (Sonic 
hedgehog) (Machold et al., 2003) and FGF (fibroblast growth factor) (Iwata and Hevner, 
2009). But interestingly, GSK-3β is involved in all four pathways.  
In general, it seems that active GSK-3β promotes neuronal differentiation whereas the 
deletion of GSK-3 (Kim et al., 2009) or the overexpression of its negative regulators (Mao 
et al., 2009; Bultje et al., 2009) enhance proliferation of NPCs but inhibit differentiation. 
Kim and co-workers were able to demonstrate the crucial role for GSK-3 in the 
development of the nervous system. A double knock-out of both, GSK-3α and β, in mice 
resulted in an increased cortical surface area with a convoluted shape, which is caused by 
an over-expansion of NPCs. The reduction of neurons leads to a thinner cortex, compared 
to control mice. In addition, they reported the phosphorylation status of GSK-3 targets. β-
catenin and c-Myc are increased during neuronal differentiation. As these two targets are 
described as proliferation-promoting factors, these results indicate that active GSK-3 
promotes neuronal differentiation. 
 
 
1.3 Small molecules and stem cells 
 
The research on small molecules has gained more and more attention within the last 
years. On the one hand, they can optimize culture conditions of cell cultures, on the other 
hand, they can manipulate cellular processes by inhibiting or activating signaling 
pathways. Thus, mechanisms of diseases can be studied, drugs can be designed.  
Of great interest is the modulation of stem cell fate by influencing the maintenance and 
differentiation of stem cells. Several small molecules have already been investigated 
regarding their influence on stem cell differentiation (Borowiak et al., 2009; Zhu et al., 
2009; Kim et al., 2009; Schneider et al., 2008). 
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The inhibition of GSK-3 by small molecules and its influence on stem cell proliferation and 
differentiation is discussed controversially. It seems that the impact of the Wnt/β-catenin 
pathway on differentiation is stage and context-specific. Inhibition of GSK-3 by BIO 
activates the transcription of Oct3/4, Rex-1 and Nanog, which are characteristic for the 
maintenance of a pluripotent, undifferentiated state in human and mouse ESCs (Sato et 
al., 2004). CHIR99021 promotes ESCs self renewal in combination with two MEK 
(MAP/ERK pathway) inhibitors (Ying et al., 2008). In contrast, treatment of NPC with 
different GSK-3 inhibitors I3M (indirubine-3-monoxime) and KP (kenpaullone) promotes 
dopaminergic differentiation of rat mecencephalon precursors (Castelo-Branco et al., 
2004).  
But not only in stem cells small molecules are of interest. Reprogramming of somatic cells 
to pluripotent cells with the characteristics similar to embryonic stem cells create a new 
way to study differentiation processes, but also enables research on various diseases. 
There are several advantages of iPSC (induced pluripotent stem cells) over embryonic 
stem cells (ESC). The most prominent is the “never-ending source”, but iPSC can also be 
generated out of patient’s cells, which would be of great benefit regarding 
transplantation studies. The low reprogramming rates and the need of the four 
transcription factors which have oncogenic potential are still a big problem (Palma et al., 
2008; Wei et al., 2006; Chen et al., 2006; Chiou et al., 2008; Knoepfler, 2008). Small 
molecules have already been shown to improve the reprogramming efficiency (Shi et al., 
2008; Huangfu et al., 2008 a and b; Li et al., 2009) as well as the substitution of up to two 
transcription factors (Shi et al., 2008; Huangfu et al., 2008 a and b). 
Small molecules offer a great potency, varying from standardization of culture conditions 
to improvement of experimental results. 
 
 
1.4 Aim of this study 
 
Wnt signaling has been shown to be involved in cellular processes in NPCs such as 
proliferation and differentiation. In this work, we used a human neural progenitor cell 
line, ReNcell VM (Millipore, Billerica, USA), which is derived from the ventral midbrain of a 
10-week-old fetus and immortalized by v-Myc retroviral transduction. This cell line is 
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characterized by rapid proliferation and can be easily differentiated into astrocytes, 
neurons and oligodendrocytes (Donato et al., 2007; Morgan et al., 2009). Previous studies 
done by our group have shown that this cell line responds to the stimulation of Wnt/β-
catenin signaling with increased neuronal differentiation (Hübner et al., 2010).  
Potent GSK-3β inhibitors offer a great promise as to the manipulation of Wnt-connected 
cell proliferation and differentiation. In addition, they could be useful for investigations 
into, or therapy of any disease that is linked to a malfunction of GSK-3β, such as diabetes, 
bipolar disorders, or Alzheimer’s disease.  
Therefore, the aims of this study were  
 
- To establish a multi-step screening system for novel GSK-3β inhibitors 
o How does the Wnt/β-catenin pathway react to GSK-3 inhibition? 
o What are the optimal read-outs for a multi-level screening system? 
 
- To study the influence of GSK-3β inhibition on hNPC 
o What is the influence on hNPC proliferation and differentiation? 
 
Potential novel GSK-3β inhibitors were provided by the Leibniz-Institute for Catalysis 
(LIKAT), Prof. Dr. Matthias Beller. 
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2 Material and Methods 
 
2.1 Material 
 
2.1.1 Technical equipment 
 System Company 
camera DS2M Nikon 
cell culture microscope Eclipse TS100 Nikon 
fluorescence microscope Biozero Keyence 
cell counter CASY Roche 
incubator  Binder 
sterile working bench Antares 48 Sterile 
centrifuge Z383K Hermle 
centrifuge Z233MK-2 Hermle 
centrifuge Universal 30 RF Hettich 
balance MCBA 100 Sartorius 
FACS FACSCalibur Becton Dickenson 
heating block Thermomixer eppendorf 
luminometer LB 9508 Berthold 
nucleofector NucleofectorII Amaxa 
pH-meter Mettler Toledo 
pipets reference eppendorf 
plate reader Magellan Tecan 
real-time PCR Cycler LightCycler 1.5 Roche 
vortexer MS1 IKA 
Table 1: Technical equipment. 
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2.1.2 Chemicals 
 
Routinely used chemicals were purchased with “pro analysis“ grade and were supplied, if 
not otherwise stated, by Calbiochem, Fluka, Merck, Sigma and Roth. 
 
2.1.3 Buffers 
 
RIPA-buffer (lysis buffer for cell extracts) 
 20mM Tris pH 7.4 
137mM NaCl 
0.1% SDS 
0.1% sodiumdesoxycholate 
1% Triton X-100 
10% glycerol 
2mM EDTA 
1mM EGTA 
1mM NaF 
20mM sodiumpyrophosphate  
plus protease and phosphatase inhibitor cocktail (Roche) 
 
PBS  
 137nM NaCl 
 2.7nM KCl 
 8.1nM Na2HPO4 
 1.5nM KH2PO4 
 
Washing buffer (ELISA) 
 0.05% Tween20 in PBS, pH 7.2-7.4 
 
IC-Diluent #1/Blocking solution (ELISA) 
 1% BSA in PBS, pH 7.2-7.4 
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IC-Diluent #4 (ELISA) 
 1mM EDTA 
 0.5% Triton X-100 in PBS, pH 7.2-7.4 
 
FACS fixing solution 
 1% PFA in PBS 
 
FACS saponin buffer 
 0.5% BSA 
0.5% saponin 
0.02% NaN3 in PBS 
 
FACS wash buffer 
 0.5% BSA 
0.02% NaN3 in PBS 
 
Blocking buffer (immunocytochemistry) 
 5% normal goat serum 
0.3% Triton-X100 in PBS 
 
Antibody incubation buffer (immunocytochemistry) 
 1%  normal goat serum in PBS 
 
 
2.1.4 Cell culture media, buffers and supplements 
 
DMEM  
(Dulbecco’s Modified Eagle Medium) 4.5g/l glucose Invitrogen 
DMEM/F12       Invitrogen 
HBSS (Hank’s balanced salt solution)   Invitrogen 
FCS (fetal calf serum)      Invitrogen  
Pen/Strep 100x      PAA 
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Gentamycin       Invitrogen 
B27        Invitrogen 
bFGF        Roche  
EGF        Roche 
heparin sodium salt      Invitrogen 
Trypsin/EDTA       Invitrogen 
Trypsin-Inhibitor      Sigma 
Trypsin/Benzonase solution 25U/ml Benzonase in Trypsin-
EDTA 
Trypsin-inhibitor/Benzonase 1% HSA, 25 /ml Benzonase, 
0.55mg/ml trypsin-inhibitor in 
DMEM/F12 
Benzonase       Merck 
mouse laminin      Trevigen 
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2.2 Methods 
 
2.2.1 Cell culture 
 
2.2.1.1 Cultivation of ReNcell VM 
 
ReNcell VM were initially provided by ReNeuron (Guildford, UK) and can meanwhile be 
purchased from Millipore (Billerica, USA). ReNcell VM are derived from the ventral 
midbrain of a 10-week-old fetus and immortalized by retroviral v-Myc transduction. They 
were cultivated in culture vessels at 37°C, 20% O2 and 5% CO2. To grow cells in adherent 
monolayers, vessels need to be coated with Laminin (stock 1mg/ml) (Trevigen, 
Gaithersburg, USA), diluted 1:100 in ice-cold DMEM:F12 (Invitrogen) for at least one hour 
at 37 °C. 
Cells were grown until 80% confluency and harvested by incubating at 37°C with 
Trypsin/Benzonase until detaching. Reaction was stopped by the addition of 
Trypsininhibitor/Benzonase. The suspension was centrifuged for 5min at 1500rpm. The 
supernatant was discharged and the cell pellet was resuspended in fresh medium with 
growth factors. A defined cell number was seeded in fresh culture vessels. 
Differentiation of cells was induced by the removal of growth factors by changing the 
medium. 
 
2.2.1.2 Cultivation of ST14A cells 
 
ST14A cells, a conditionally immortalized rat embryonic (E14) striatal progenitor cell line 
with a temperature-dependent expression of an immortalizing oncogene, have been 
described before (Cattaneo et al., 1998). The cells were obtained from embryonic day 14 
(E14) rat striatum and were transfected with the temperature-sensitive mutant tsA58U19 
of the SV40 large T antigen (Weinelt et al., 2003) Cells were cultured in flasks and 
chamber slides at 33°C for proliferation and 39°C for differentiation, respectively. 
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2.2.1.3 Determination of cell number 
 
The number of cells was counted using a CASY cell counter (Roche, Germany). On passing 
the measurement capillary a determined amount of electrolyte solution is displaced by 
the cells. This results in a change resistance which is a dimension for the cell volume. This 
technique allows separate viable from dead cells as dead cells are smaller and therefore 
have a different resistance. 
A defined volume of cell suspension was added to 10ml CASYton and measured with the 
appropriate calibrated program.  
 
2.2.1.4 Transfection of cells 
 
For the transfection of ReNcell VM with either overexpression or reporter gene plasmids 
the Nucleofection System (Lonza, Cologne, Germany) together with Nucleofector Kit V 
was used. Briefly, 2x106 cells were resuspended in Nucleofection solution and transfected 
with 2µg plasmid and program X-001 according to the manufacturer’s instructions. 
Subsequently, cells were plated in laminin-coated culture vessels and grown up to 80% 
confluence. Cells were then differentiated by the withdrawal of growth factors. Small 
molecules were added at the start of differentiation, diluted in differentiation medium. 
 
2.2.1.5 Cell proliferation assay 
 
Cells were seeded at a defined cell number and proliferated for 24h. Then the medium 
was changed and substances or DMSO as a control were added at an appropriate 
concentration (timepoint 0h). The cell number and viability were measured every day by 
using the CASY cell counter system. For each time point a triplicate was determined. 
 
2.2.1.6 WST-1 assay 
 
Cell viability was measured using the colorimetric assay WST-1 (Roche, Penzberg, 
Germany) that determines the enzyme activity of mitochondrial dehydrogenases, which 
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cleave a tetrazolium substrate resulting in colored formazan. The enzyme activity 
correlates with the metabolic activity of viable cells (Hipper and Isenberg, 2000). 10000 
cells per well were seeded in laminin-coated 96-well plates in proliferation medium. 
Drugs were applicated 24h after cell seeding in either proliferation or differentiation 
medium. Cell viability was assessed after 24h and 48h by adding 10µl WST-1 reagent (10% 
of the total volume) per well and incubation of the plates for 2h at 37°C and 5% CO2. The 
optical density at 450nm wavelength was determined using genios microplate reader 
(Tecan, Crailsheim, Germany). 650nm was used as reference wavelength. Per condition, 
six wells were measured.  
 
2.2.2 Molecularbiological methods 
 
2.2.2.1 RNA-isolation  
 
RNA was isolated by using the RNeasy Plus Mini Kit (Qiagen, Hilden). Briefly, cells were 
harvested (2.2.1.1), centrifuged for 5min at 300xg. The pellet was resuspended in 400µl 
RLT plus buffer. 5x106 cells were used to isolate RNA according to the manufacturer’s 
instructions. RNA was eluted in 2x 30µl RNAse free water. The quantity and quality of 
total RNA was determined by spectroscopy (2.2.2.2) and denaturating agarose gel 
electrophoresis (2.2.2.3). Samples were stored at -80°C. 
 
2.2.2.2 Photometric RNA concentration measurement 
 
The quantity and quality of total RNA were analyzed by measuring the absorption at 260 
and 280nm using a spectrophotometer (Nanodrop, ThermoScientific, Wilmington, USA) 
and denaturating agarose gel electrophoresis (2.2.2.3). A 260/280nm ratio of 1.8-2.0 
indicated high qualtity RNA.  
 
 
Material and Methods  20 
 
2.2.2.3 RNA agarose gel electrophoresis 
 
For the integrity check of RNA samples, RNA was separated using formalydehyde gels. 
Gels were generated by adding 10ml of 10x FA gel buffer and 90ml RNase free H2O to 
1.2g agarose. The mixture was heated to melt agarose and then cooled to 65°C. 1.8 ml of 
37% (12.3M) formaldehyde and 1μl of a 10mg/ml ethidium bromide stock solution were 
added, mixed and poured onto the gel support. The gel was equilibrated in 1x 
formaldehyde gel running buffer for 30min. RNA samples were mixed with the 
appropriate volume of 2x RNA loading dye (MBI Fermentas, St.-Leon-Roth Germany). The 
gels were run at 100V and photographed using UV gel documentation system (Herolab, 
Wiesloch, Germany) in combination with a digital camera sytem (C-5050; Olympus, 
Japan). Size estimation of RNA fragments was done using marker RiboRuler (MBI 
Fermentas). Sharp bands of 28S/18S rRNA with an intensity ratio of about 2:1 indicated 
intact RNA. 
 
2.2.2.4 TaqMan quantitative real-time PCR 
 
A customized 384-well format TaqMan Array (Applied Biosystems Inc, Foster, USA) was 
used for gene mRNA quantification. The first cDNA strand was synthesized with 400ng of 
total RNA as template using High Capacity cDNA kit (Applied Biosystems) according to the 
manufacturer’s instruction. Each slot was loaded verb missing equivalently with cDNA 
transcribed from 200ng RNA. Samples were run in duplicate on a 7900HT real-time PCR 
system (ABI).  
Cycling parameters were as followed: 
 
Enzyme activation:    50°C  2min 
Initial denaturation:   95°C  20sec 
 
Denaturation:    95°C  1sec 
 
Annealing and extension:  60°C  20sec 
 
45x 
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The threshold line was set automatically by SDS 2.3 software and the threshold cycle (CT) 
values were determined by the threshold line crossing the amplification curve. Target 
transcription abundance was quantified using the delta-delta CT method. PCR data were 
normalized to GAPDH and expressed as relative changes compared to timepoint 0h.  
 
2.2.2.5 Luciferase reporter gene assay 
 
For the analysis of TCF-dependent transcription ReNcell VM cells were transfected with 
p12xSuperTOPFlash vector or p8xFOPflash and renilla luciferase vector phRL-TK (kindly 
provided by Randall T. Moon) with the Nucleofection system (Lonza, Cologne, Germany), 
according to the manufacturer’s recommendation. As a positive control, cells were co-
transfected with the vector pCAGGS-S33Y containing a stabilized form of β-catenin. In this 
vector, the phosphorylation site Ser33 is replaced by Tyrosine, resulting in a constitutively 
active form (Kim et al., 2000). Subsequently cells were plated in laminin-coated 48-well 
plates and cultured as described above. 24h after transfection, the proliferation 
conditions were changed to differentiation conditions. At the start of differentiation, 
drugs were added at indicated concentrations. The activity of the firefly luciferase and 
constitutively expressed Renilla luciferase was measured using the luminometer LB 9508 
(Berthold, Bad Wildbad, Germany) and the Dual Luciferase Assay Kit (Promega, Madison, 
USA). 
 
2.2.3 Protein analysis 
 
2.2.3.1 Protein determination 
 
The amount of protein in ReNcell VM cells extracts was determined by the use of the BCA 
protein assay reagent kit (Thermo Scientific, Rockford, USA). Cells were lysed with RIPA 
buffer supplemented with protease and phosphatase inhibitors (Roche) and centrifuged 
for 5min at 15000rpm. The supernatant was used for further experiments. 200µl BCA 
reaction solution were added to 10µl of total cell protein and incubated for 1h at 37°C. 
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The absorbance was measured at 570nm with a plate photometer (Tecan, Crailsheim, 
Germany). 
 
2.2.3.2 ELISA 
 
The stabilization of β-catenin was measured using the human total β-catenin ELISA 
DuoSet IC system (R&D Systems, Wiesbaden, Germany) according to the manufacturer’s 
recommendation. 15µg of total cell lysate were used. The optical density was measured 
with a plate photometer (Tecan) at 450nm with a wavelength correction at 570nm. 
Cells were differentiated 24h after seeding for 2h. The substances were added at 
indicated concentrations at the start of differentiation.  
 
2.2.3.3 GSK-3β activity assay 
 
IC50 of new synthesized compound AB199 to GSK-3β was determined by a luminometric 
GSK-3β activity assay. This method has been described by Baki et al. (2007) and gives IC50 
values comparable to a radioactive detection. Briefly, compounds were tested in different 
concentrations diluted in assay buffer containing final concentrations of: 4mM MOPS pH 
7.2; 0.4mM EDTA; 1mM EGTA; 2.5mM β-glycerophosphate; 4mM MgCl2; 40µM BSA; 
0.05mM DTT. 4µl of diluted compounds were added to 25µM pGS-2 peptide substrate 
(Millipore, Billerica, USA), 20ng recombinant GSK-3β (R&D systems) and 1µM ATP (Cell 
Signaling, Boston, USA) to a total assay volume of 40µl. The enzymatic reaction was 
stopped after 30min of incubation at 30°C by adding 40µl KinaseGlo (Promega, Madison, 
USA). The luminometric signal was allowed to stabilise for 10min and then measured with 
a Glomax® 96 Microplate Luminometer (Promega). 
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2.2.3.4 GSK-3β in vitro kinase assay 
 
ReNcell VM cells were differentiated at 80% confluence for 2h. The test substances were 
added at the start of differentiation at indicated concentrations.  
Cells were lysed in RIPA buffer, supplemented with protease and phosphatase inhibitors 
(Roche, Mannheim, Germany) and centrifuged for 5min at 15000rpm. The supernatant 
was used for further experiments. Immunoprecipitation of GSK-3β was performed with a 
specific mouse monoclonal anti GSK-3β [G8] antibody (Abcam, Cambridge, UK) with 
5µg/sample for 2h at 4°C. The bound protein was precipitated with Protein A/G-Plus 
agarose-beads (10µl beads per sample; Santa Cruz Biotechnology, Santa Cruz, USA). GSK-
3β kinase activity was measured in a reaction mixture containing final concentrations of: 
4mM MOPS pH 7.2; 0.4mM EDTA; 1mM EGTA; 2.5mM β-glycerophosphate; 4mM MgCl2; 
40µM BSA; 0.05mM DTT. 10µg/sample pGS-2 peptide substrate (Millipore, Billerica, USA) 
was used. 
The assay was initiated by the addition of a mixture of unlabelled ATP (final 
concentration: 50 µM) and [γ-32P] ATP (Hartmann Analytic, Braunschweig, Germany; 4µCi 
per sample). Following 20min incubation at 37°C the assay was stopped by centrifugation 
at 10,000g  for 1min and spotting the supernatant onto phosphocellulose discs. The filter 
mats were washed once in 1% acetic acid and 3 times in H2O. Afterwards, pGS-2 peptide-
associated γ-32P radioactivity bound to the phosphocellulose was quantified by Cerenkov 
counting. 
 
2.2.3.5 Immunocytochemistry 
 
ReNcell VM cells were cultured and differentiated as above. Shortly, ReNcell VM were 
seeded on cover slips and proliferated for 3 days and subsequently differentiated by the 
withdrawal of growth factors. Cells were fixed with 4% PFA in 0.1% PBS for 15min, at time 
points 0h and 3 days, whereas 0h was the time point of the induction of differentiation. 
Afterwards the cells were treated with blocking solution containing 0.4% TritonX-100 for 
30 min at room temperature. The primary antibody for βIII-tubulin (Santa Cruz, 1:500 
mouse monoclonal) was incubated for 1hr as well as the secondary antibody (Alexa Fluor 
568 goat anti rabbit, 1:1000, Molecular Probes). Probes were sealed with mounting 
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medium containing DAPI (1.5µg/ml, Vector Labs, USA) as a marker for cell nuclei. 
Microscopic analysis was performed using the Keyence Biozero system (Keyence, Neu-
Isenburg, Germany). 
ST14A cells were cultured in 8-well chamber-slides under proliferation conditions. With 
the change to differentiation conditions, a media change was performed and the drugs 
were added at indicated concentrations to the media. At time points 0h and 6h, the cells 
were fixed with 4% paraformaldehyde in 0.1% PBS for 10min. After washing, unspecific 
binding sides were blocked with PBS containing 0.3% Triton X-100 and 5% goat serum for 
30min. Cultures were incubated with the primary antibody for 30 min at room 
temperature. β-catenin specific antibody (mouse mAb, Santa Cruz, Heidelberg, Germany) 
was diluted 1:200 in PBS with 1% goat serum. The slides were washed with PBS and then 
incubated with the secondary antibody (Alexa Fluor 568 goat anti-mouse antibody, 
diluted 1:100 in PBS with 1% goat serum) for 30min at room temperature. After washing 
with PBS, the cells were covered with mounting medium (Vector Labs, Burlingame, CA, 
USA) containing DAPI (1.5μg/ml) for nuclear staining. Microscopic analysis was performed 
using the Keyence Biozero microscope (Keyence). 
 
2.2.3.6 Flow cytometry 
 
The influence of GSK-3β inhibitors on neuronal differentiation of ReNcell VM cells was 
determined by FACS analysis. Cells were stained for βIII-tubulin and the total number of 
positive cells was measured. For this purpose cells were cultured in 6-well plates up to 
80% confluency and subsequently differentiated for 3 days. The medium supplemented 
with substances was changed every 24h. For FACS analysis, cells were trypsinized and 
centrifuged at 100xg at RT for 5min, washed with PBS without Ca2+ and Mg2+ and fixed 
with 1% PFA in PBS for 15min. Cells were then resuspended in washing buffer (PBS + 0.5 
% BSA + 0.02 % Na-azide) and stored at 4°C in the dark. For the staining cells were 
centrifuged and resuspended in saponin buffer (PBS + 0.03% saponin + 0.5% BSA + 0.02% 
Na-azide) containing βIII-tubulin antibody (Santa Cruz, 1:100 mouse monoclonal) and 
incubated for 2h at RT. Afterwards the cells were washed and incubated with the 
secondary antibody (Alexa Fluor 647 goat-anti-mouse, 1:1000, Molecular Probes) for 1h 
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in saponin buffer. Cells were washed twice with saponin buffer and resuspended in wash 
buffer for analysis. Measurement was done using FACSCalibur (BectonDickinson, San Jose, 
USA) in combination with Cell Quest Pro software. 
 
2.2.3.7 Apoptosis assay 
 
ReNCell VM cells were cultured under proliferation conditions up to 80% confluence. 
Then cells were differentiated for up to 12h in the presence of 3µM SB-216763, AB199 or 
the equivalent amount of DMSO. Cells were harvested and stained with Annexin/PI using 
the FITC Annexin V Apoptosis Detection Kit I (BectonDickinson) according to the 
manufacturer’s recommendation. Measurement was done using FACSCalibur 
(BectonDickinson) in combination with Cell Quest Pro software. 
 
2.2.4 Statistical analysis 
 
All results are shown as mean ± SEM of data, whereat N indicates the number of 
biological repeats and n the number of technical repeats. Statistical analysis was 
performed with a Student’s t-test. p< 0.05 was considered to indicate statistically 
significance using Excel (Microsoft, USA) and Prism5 (GraphPad Prism Inc., USA). 
Results  26 
 
3 Results 
 
3.1 Screening for a new GSK-3β inhibitor 
 
In order to develop a screening system for novel GSK-3β inhibitors in hNPCs, potential 
targets/readouts to investigate their influence on Wnt/β-catenin signaling and its effect 
on hNPC proliferation and differentiation were tested regarding their applicability for a 
multi-level screening system. Potential targets were chosen by downstream-events of 
GSK-3β inhibition. 
 
 
 
Figure 4: Potential readouts for a screening system for a novel GSK-3β-inhibitor. 
 
3.1.1 Time-dependent accumulation of β-catenin  
 
As the phosphorylation and degradation of cytosolic β-catenin is mediated by GSK-3β as a 
member of the β-catenin degradation complex, the accumulation of β-catenin was an 
attractive target for screening approaches. 
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To evaluate which timepoint is best to investigate the influence of novel small molecules 
on β-catenin accumulation, the expression of β-catenin was analyzed over the time. 
ReNcell VM cells were seeded at a defined number, cultivated up to 80% confluence and 
then differentiated by the withdrawal of growth factors as described in 2.2.1.1. With the 
start of differentiation, the known GSK-3β inhibitors Kenpaullone and SB-216763 were 
added at indicated concentrations. Cells were harvested and proteins were isolated at 
defined time points (2.2.3.1). The amount of total β-catenin was determined by an ELISA 
specific for β-catenin (2.2.3.2). 
 
 
Figure 5: Total β-catenin in ReNcell VM cells after treatment with Kenpaullone and SB-216763.  
Cells were cultured for 0-48h under differentiation conditions in the presence of known GSK-3β 
inhibitors. Concentrations were 1µM for Kenpaullone (KP) and 3µM for SB-216763 (SB21). β-
catenin level was evaluated with a β-catenin specific ELISA. The level of β-catenin increases at the 
start of differentiation. This effect can even be intensified by the treatment with GSK-3 inhibitors. 
Data were normalized to 0h differentiation and represent mean +/- SEM (N=3-7, each done in 
triplicates). Values were significantly different between drug treated and DMSO treated control 
cells at *p< 0.05 or **p<0.01. 
Differentiation of ReNcell VM results in an increase of the amount of total β-catenin 
already after 1h. This rise of the β-catenin level compared to proliferating cells is constant 
up to 6h. After 12h a decrease can be seen (Fig.5). The highest amount of total β-catenin 
can be detected after 48h. Treatment of cells with SB-216763 or Kenpaullone displayed a 
similar expression profile, whereas the increase of β-catenin levels was stronger 
compared to control cells. This difference between control and drug-treated cells was 
significant after 1h and 2h of treatment, albeit the amount of total β-catenin under the 
influence of SB-216763 was slightly higher after 2h incubation (Fig.5). Therefore, time 
point 2h was chosen for further screening approaches. 
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3.1.2 Screening for novel small molecules as potential GSK-3β inhibitors 
 
191 novel small molecules were tested regarding their ability to increase β-catenin 
accumulation, but only substance groups AB and GK are presented in detail. The tested 
substances were provided by the Leibniz-Institute for Catalysis. 
 
Figure 6: Total β-catenin in ReNcell VM cells after treatment with novel small molecules.  
Cells were cultured for 2h under differentiation conditions in the presence of known GSK-3β 
inhibitors or new synthesized small molecules. β-catenin level was evaluated with a β-catenin 
specific ELISA. Concentrations were 1µM for Kenpaullone (KP) and 3µM for SB-216763 (SB21) and 
substances, respectively. Data were normalized to DMSO control and represent mean +/- SEM 
(N=3-4, each done in triplicates).  
As shown in Fig.6, none of the newly designed small molecules (AB-substances, Fig.7) was 
able to increase β-catenin accumulation in the same range as SB-216763. Several 
substances reached the same level as Kenpaullone. One substance which resulted in a 
similar action as Kenpaullone was AB199, highlighted in red. To investigate if any 
modifications of AB199 could improve its effects, 12 derivatives of AB199 (GK-substances, 
Fig.8) were tested. None of the modifications showed an improvement in β-catenin 
accumulation. Therefore, AB199 alone was characterized in a detailed way, regarding its 
influence on the Wnt/β-catenin pathway as well as functional assays regarding 
proliferation and differentiation of human neural progenitor cells.  
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Figure 7: Chemical structures of various non-symmetrically substituted indolylmaleimides 
tested for biological activity. 
 
 
 
Figure 8: Small chemical library based on AB199. 
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3.1.3 Characterization of potential GSK-3β inhibitor AB199 
 
3.1.3.1 Determination of the ideal working concentration of AB199 in hNPC 
 
To determine the concentration of AB199 with the optimal biological response in hNPC, 
seven concentrations of AB199 from 0.1µM to 10µM were measured. First, the influence 
of different concentrations of SB-216763 and AB199 on cell metabolic activity as a cellular 
toxicity assay was tested. WST is a tetrazolium salt which is cleaved by mitochondrial 
dehydrogenases into formazan (Berridge et al, 1996). The amount of formed formazan 
correlates with the metabolic activity of the cells and can be measured photometrically. 
Drugs were diluted in either proliferation or differentiation medium and applied to the 
cells. Medium with fresh drugs was changed every 24h, and cell metabolic activity was 
measured 24h and 48h after initial drug application (2.2.1.6). Concentrations from 1µM to 
3µM were tested. It could be observed that none of the tested concentrations had a toxic 
effect on hNPCs, whereas the treatment with SB-216763 for 24h increased cell metabolic 
activity (Fig.9a). The same effect could be observed in a concentration-dependent manner 
for AB199, but this effect was not significant (Fig. 9c). Any significant changes for SB-
216367 under differentiation conditions are of statistic origin (Fig. 9b). AB199 slightly 
diminishes cell metabolic activity after 24h under differentiation conditions (Fig. 9d). 
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Figure 9: Metabolic activity in proliferating and differentiating hNPC under the influence of SB-
216763 and AB199.  
Cells were cultivated under proliferation or differentiation conditions in the presence of SB-
216763 (SB21) or AB199 from 1-10µM. After 24h and 48h, cell metabolic activity was measured 
with WST-1 assay. None of the tested concentrations of both drugs had a toxic effect on cell 
metabolic activity of hNPC. Data were normalized to DMSO control cells and represent mean +/- 
SEM (N=4, each done in sextuplets). Values were significantly different between drug treated and 
DMSO treated control cells at *p< 0.05 or **p<0.01. 
As none of the tested concentrations was revealed to be toxic, concentrations of AB199 
from 0.1 to 10µM were investigated regarding their ability to accumulate β-catenin. 
Therefore an ELISA specific for human total β-catenin was used (2.2.3.2). At 
concentrations from 0.1µM to 3µM a concentration-dependent increase of β-catenin 
accumulation from equal to 1.3-fold compared to control cells could be observed (Fig. 
10a). This effect rapidly decreased when concentrations of AB199 from 5-10µM were 
used, indicating a tight dose-window. An EC50-concentration of 3.8µM was calculated, 
whereat a bell-shaped dose-response curve was monitored. Therefore the use of 3µM for 
further experiments was reasonable. 
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Figure 10: Total β-catenin in ReNcell VM after treatment with different concentrations of 
AB199. 
A: AB199 augmented β-catenin accumulation significantly at a concentration of 3µM. Lower or 
higher concentration had no further effect. B: EC50 determination for β-catenin accumulation. 
Cells were cultured for 2h under differentiation conditions in the presence of AB199. 
Concentrations were 1µM for Kenpaullone (KP), 3 µM for SB-216763 (SB21) and variable for 
AB199. Data were normalized to DMSO control and represent mean ± SEM (N = 3–10, each done 
in triplicates). Values were significantly different between drug treated and DMSO treated control 
cells at *p <0.05 or **p <0.01. 
 
Furthermore it was of interest to examine whether combinations of AB199 with SB-
216367 could even ameliorate the single observed effect. Thus, SB-216763 at a 
concentration of 3µM was combined with various concentrations of AB199, ranging from 
0.1-10µM and were tested regarding their potency to accumulate β-catenin. 
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Figure 11: The combination of SB-216763 and AB199 resulted in no additive effect to SB-216763.  
Cells were cultured for 2 h under differentiation conditions in the presence of AB199. 
Concentrations were 1µM for Kenpaullone (KP), 3µM for SB-216763 (SB21) and variable for 
AB199. Data were normalized to DMSO control and represent mean ± SEM (N = 3–10, each done 
in triplicates). Values were significantly different between drug treated and DMSO treated control 
cells at *p <0.05 or **p <0.01. 
 
As shown in Fig.11 no additive effect to SB-216763 was observed. Interestingly, the 
combination of 3µM SB-216763 and 10µM of AB199 depleted the β-catenin level in a 
significant way, whereas 3µM SB-216763 together with lower concentrations of AB199 
(0.1–5µM) showed no effect. 
 
3.1.3.2 Inhibition of GSK-3β by AB199 
 
As AB199 showed to accumulate β-catenin in hNPC, its mechanism of action was of 
interest. Due to its close structural similarity to SB-216763, it is most likely that AB199 
inhibits GSK-3β. In order to prove this assumption an in vitro kinase assay. hNPC were 
treated for 2h with either SB-216763 or AB199 under differentiation conditions. Cells 
were then lysed and total protein was isolated. GSK-3β was immunoprecipitated by a 
specific antibody. Remaining kinase activity was measured by phosphorylation of GSK-3β 
substrate and ATP-consumption (2.2.3.4). 
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Figure 12: Inhibition of GSK-3β by SB-216763 and AB199.  
Cells were cultured for 2h under differentiation conditions in the presence of AB199. 
Concentrations were 1µM for Kenpaullone (KP), 3µM for SB-216763 (SB21) and variable for 
AB199. GSK-3β was immunoprecipitated and remaining activity was measured by the turnover of 
ATP. The known GSK-3β inhibitor downregulated GSK-3β activity to 22 ± 18%. AB199 acted in the 
same range and inhibited GSK-3β to a remaining activity of 27 ± 5%. Data represent mean ± SEM 
(N = 3). Values were significantly different between drug treated cells and DMSO treated control 
cells at *p <0.05 and **p <0.01. 
 
These results suggest that AB199 acts as a GSK-3β inhibitor. To determine its sensitivity, a 
GSK-3β activity assay was performed. Here, GSK-3β was not immunoprecipitated out of 
hNPC but a recombinant enzyme was used. This assay makes it possible to investigate the 
direct effect on GSK-3β and does not take into consideration any effect of other cellular 
activities on the enzyme. 
 
An IC50 for the inhibition of GSK-3β was obtained by treating recombinant GSK-3β with 
different concentrations of either SB-216763 or AB199. Remaining activity was measured 
as a luminometric signal which is inversely correlated with kinase activity (2.2.3.3). 
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Figure 13: Inhibition of GSK-3β by SB-216763 and AB199.  
IC50 value for GSK-3β inhibition by SB-216763 (A) and AB199 (B) were determined in a kinase 
activity assay. The luminescence signal is inversely correlated with kinase activity. The evaluation 
revealed IC50 values of 92nM for SB-216763 and 53nM for AB199. Data were normalized to 
control and represent mean ± SEM (n = 3–8). 
 
The experiments revealed that both substances inhibit GSK-3β in a dose-dependent 
matter. For SB-216763, an IC50 value of 92nm was calculated (Fig. 13a). The IC50 value for 
AB199 was slightly lower with 53 nM (Fig. 13b). Interestingly, a bell-shaped dose-
response curve was observed for AB199, whereas the dose-response curve displayed a 
sigmoidal run. The same bell-shaped run under AB199-conditiong was observed for beta-
catenin accumulation (Fig. 10b) 
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3.2 Influence of novel GSK-3β inhibitor AB199 on Wnt/β-catenin signaling 
 
GSK-3β is the key enzyme of the Wnt/β-catenin pathway. It forms, together with APC, CK1 
and Axin, the β-catenin degradation complex (MacDonald et al., 2009), which triggers the 
phosphorylation and ubiquitination of β-catenin, resulting in activation of the Wnt-
pathway. Inhibition of GSK-3β results in the accumulation of β-catenin and the activation 
of Wnt downstream targets. 
 
3.2.1 Nuclear accumulation of β-catenin mediated by AB199 
 
To visualize nuclear β-catenin, a cell line derived from rat striatum (ST14A) was treated 
with either SB-216763 or AB199 and immunocytochemically stained for β-catenin. ST14A 
cells have been described previously as a model for visualizing nuclear accumulation of β-
catenin, whereas ReNcell VM in our hands did not show a clear accumulation of β-catenin 
which was most likely due to the growth pattern of the cells (Fig. 14). 
 
 
Figure 14: Nuclear β-catenin translocation in ReNcell VM cells and ST14A cells. 
hNPCs (A+B) and ST14A cells (C+D) were differentiated for 1d and stained for β-catenin (red) and 
DAPI (blue). hNPCS (A+B) show a dense growth pattern, cell boarders cannot be identified. ST14A 
cells (C+D) are larger and display a flat morphology. Cells are clearly separated from each other, 
single cells can be seen. Arrows indicate nuclear β-catenin accumulation. The scale bar indicates a 
size of 20µm.  
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Figure 15: GSK-3β inhibitors elevate nuclear β-catenin accumulation after 6 h of differentiation. 
ST14A cells were stained for β-catenin (red) and DAPI (blue). Left panel: (A) In DMSO treated cells 
no β-catenin accumulation was observed. In contrast, in SB-216763 (SB21) (B) or AB199 (C) 
treated cells, an accumulation of β-catenin around the nucleus was observed. Right panel: The 
peri-nuclear accumulation is also visible in a line-scan detecting the fluorescence intensity (F568) 
of the cytosol (C) and nucleus (N). Arrows indicate the peri-nuclear accumulation of β-catenin. The 
scale bar indicates a size of 10µm.  
 
When cells were differentiated for 6h, cells showed no nuclear accumulation of β-catenin 
(Fig. 15a). Treatment with SB-216763 led to a clear enrichment of β-catenin (Fig. 15b). 
This was confirmed with a linescan, which quantifies the fluorescence intensity. AB199 
was able to imitate this effect, showing that AB199 not only inhibits GSK-3 and increases 
β-catenin accumulation but also triggers its translocation to the nucleus (Fig. 15c). 
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3.2.2 Induction of TCF-activity 
 
After β-catenin has been translocated to the nucleus, it replaces Groucho and interacts 
with the TCF/LEF transcription factors and activates the transcription of Wnt target genes. 
The activity of those transcription factors can be measured with a reporter gene assay. 
hNPCs were transfected with  TOPFlash (containing 12 TCF binding sites), FOPFlash (a 
control vector which contains mutant TCF binding sites). Previous experiments revealed 
that a co-transfection with pCAGGS-S33Y was necessary, a vector which includes a 
mutated, stabilized form of β-catenin, to detect TCF-activity in these cells. It seems that a 
certain threshold of β-catenin has to be overcome. As the accumulation of β-catenin had 
already shown to be time-dependent, several time points were analyzed regarding their 
TCF-activity. 
 
 
Figure 16: TCF-activity of hNPC after treatment with SB-216763 and AB199.  
Cells were transfected with TOP/FOP plasmids and co-transfected with pCAGGS-S33Y (TCF 
reporter gene assay SuperTOPflash). 24 hours after transfection, conditions were changed from 
proliferation to differentiation with the addition of small molecule at a concentration of 3µM. 
TCF-activity was measured after 0-24h of differentiation. Ratio TOP/FOP was normalized to 
control cells. Data represent mean ± SEM (N = 5, each done in triplicates). Values were 
significantly different between drug treated cells and DMSO treated control cells at *p <0.05 and 
*p<0.01. 
 
The induction of differentiation of hNPCs by the withdrawal of growth factors led to 
decrease of TCF-activity after 6h, but then to a time-dependent increase (Fig. 16, black 
column). This suggests that Wnt, together with the time-dependent accumulation β-
catenin after start of differentiation, that Wnt/β-catenin signaling is involved in the 
differentiation process of hNPCs. SB-216763 influenced TCF-activity in a positive way, 
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compared to control cells, resulting in a peak after 18h of differentiation (2.3 fold 
compared to 0h) followed by a decrease (Fig. 16, grey column). AB199 can even boost this 
effect, which is clearest after 24h (1.5 fold by SB-216763 and 3.2 fold by AB199, compared 
to 0h). 
 
3.2.3 Gene expression-profile of components of the Wnt/β-catenin pathway 
 
As it has been successfully shown that GSK-3β inhibition results in an upregulation of TCF-
activity, it was of interest to examine how GSK-3β inhibition manipulates the gene 
expression of components of the Wnt/β-catenin signaling pathway or Wnt target genes. 
hNPCs were differentiated for up to 4 days in the presence of either DMSO (control), SB-
216763 or AB199. At defined time points, cells were harvested and total RNA was isolated 
(2.2.2.1). Isolated RNA was transcribed into cDNA and then analyzed with a customized 
TaqMan array (2.2.2.4).  
 
3.2.3.1 Expression of Wnt receptors 
 
It has been previously shown that hNPCs can respond to Wnt/β-catenin signaling as they 
express endogenously Wnt receptors and respond to ligand-binding (Mazemondet et al., 
in preparation). Native differentiation was characterized and revealed an increase in 
expression of Wnt receptors. Therefore it was of interest to investigate the effect of GSK-
3β inhibitors on the expression of Wnt receptors. 
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Figure 17: Expression of Wnt signaling receptors. 
hNPCs were differentiated up to 96h under the influence of 3µM SB-216763 (SB21), 3µM AB199 
or the equivalent amount of DMSO. Cells were harvested at indicated time points and mRNA 
levels of Frizzled receptors (Fzd) were detected by TaqMan quantitative real-time PCR. Values 
were normalized to GAPDH. Data were normalized to 0h differentiation and represent mean +/- 
SEM (N=4, each done in duplicates). Values were significantly different at *p< 0.05 or **p<0.01. 
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All Frizzled-Rezeptors could be detected in hNPCs, whereas Fzd8 and Fzd10 were 
expressed in a very low manner and thus could not be quantified (Tab. 2). All Frizzled-
Receptors were upregulated during differentiation, except Fzd5 which displayed 
decreased expression. Treatment with GSK-3β inhibitors resulted in no severe changes in 
expression profiles (Fig. 17), whereat AB199 showed a tendency to increase Fzd7-
expression. Fzd9-expression was downregulated under the influence of SB-216367, but 
this effect was not significant. This effect could not be counterfeited by AB199 (Fig. 17h). 
 
3.2.3.2 Expression of Wnt signaling co-receptors 
 
In addition to the determination of the expression of several Wnt-receptors, the 
expression profiles of different co-receptors were analyzed. Like the expression of Wnt-
receptors, the expression of co-receptors increased at the start of differentiation over the 
time. 
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Figure 18: Expression of Wnt signaling co-receptors and alternative receptors.  
hNPCs were differentiated up to 96h under the influence of 3µM SB-216763 (SB21), 3µM AB199 
or the equivalent amount of DMSO. Cells were harvested at indicated time points and mRNA 
levels of Wnt-receptors were detected by TaqMan quantitative real-time PCR. Values were 
normalized to GAPDH. Data were normalized to 0h differentiation and represent mean +/- SEM 
(N=4, each done in dublettes). Values were significantly different at *p< 0.05 or **p<0.01. 
For LRP5 and 6, some changes following small molecule-treatment could be observed. 
Expression of LRP5 was significantly downregulated after 72h under the influence of SB-
216763, compared to control or AB199-treated cells (Fig. 18a+b). The same goes for LRP6 
after 72h and 96h. Expression of Ror2 and Ryk was not significantly influenced by the 
presence of SB-216763 or AB199 (Fig. 18c+d), whereat expression Ror2 shows a massive 
increase during late differentiation, starting from time point 48h to 96h . 
3.2.3.3 Expression of Wnt ligands 
 
As only some slight changes in the expression of Wnt-receptors caused by the exposition 
of hNPCs during differentiation were monitored, we wanted to know whether they might 
have an influence on the expression of Wnt-ligands. Out of 19 Wnts, only Wnt5a, 5b, 
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Wnt7a and Wnt10b could be detected in a quantifiable manner (Fig. 19). All the others 
were either not detectable or expressed at a very low level (Tab. 2). 
 
Figure 19: Expression of Wnt ligands.  
hNPCs were differentiated up to 96h under the influence of 3µM SB-216763 (SB21), 3µM AB199 
or the equivalent amount of DMSO. Cells were harvested at indicated time points and mRNA 
levels of Wnt-ligands were detected by TaqMan quantitative real-time PCR. Values were 
normalized to GAPDH. Data were normalized to 0h differentiation and represent mean +/- SEM 
(N=4, each done in duplicates). Values were significantly different at *p< 0.05 or **p<0.01. 
The expression of Wnt5a (Fig. 19a) and Wnt7a (Fig. 19b) increased during differentiation. 
Whereas Wnt5a was upregulated up to about 35-fold after 96h, the increase of Wnt7a 
expression was about 1800-fold. Treatment with SB-216763 decreased Wnt5a-expression 
after 72h in a significant way compared to control or AB-199 treated cells. After 96h, both 
SB-216763 and AB199 treated cells showed a reduced expression of Wnt5a compared to 
control cells (Fig. 19a). 
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3.2.3.4 Expression of Wnt signaling modulators and target genes 
 
An activation of Wnt/β-catenin signaling results in the transcription of Wnt target genes. 
Our experiments have shown that the differentiation of hNPCs induces the activation of 
Wnt/β-catenin signaling, which could also be manipulated by novel GSK-3 inhibitors. 
Therefore the expression of different Wnt target genes or modulators was evaluated.  
Figure 20: Expression of Wnt signaling modulators and target genes.             
hNPCs were differentiated up to 96h under the influence of 3µM SB-216763 (SB21), 3µM AB199 
or the equivalent amount of DMSO. Cells were harvested at indicated time points and mRNA level 
were detected by TaqMan quantitative real-time PCR. Values were normalized to GAPDH. Data 
were normalized to 0h differentiation and represent mean +/- SEM (N=4, each done in 
duplicates). Values were significantly different at *p< 0.05 or **p<0.01. 
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Differentiation of hNPCs induced the expression of Axin2 and Kremen1 (Fig. 20a+e), 
whereas Dkk1 (Dickkopf1) and CCDN1 (Cyclin D1) were downregulated (Fig. 20b+d). SB-
216763 was not able to increase the expression of Axin2 significantly after different time 
points compared to control cells, which could not be observed for AB199 (Fig. 20a). In 
addition, SB-216763 changed the expression profile slightly for CCDN1. The 
downregulation of CCDN1 was not that strong in the presence of SB-216763 compared to 
control cells or AB199-treated cells (Fig. 20d). 
In conclusion, differentiation of hNPCs had a strong impact on the expression of Wnt-
related genes. Interestingly, the inhibiton of GSK-3β had only slight effects on the 
expression profile, only some genes, like Fzd7, Fzd9 or Axin2 were affected by the 
presence of GSK-3β inhibitors. Any observed modulating-effects were caused by the 
treatment of hNPCs with SB-216763, the expression profile of AB199-treated hNPCs was 
more similar to control cells.  
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Time point of 
upregulation 
Maxiumum 
increase 1-5-fold  
Maxiumum 
increase 5-10-fold 
Maxiumum 
increase >10-fold 
0-6 hours    
6 hours-2 days c-Myc 
 
Fzd2 
Fzd7 
Fzd9 
LRP5 
LRP6  
Ryk  
Axin2 
Fzd3 
WNT5A 
WNT7A 
Ror2 
 
>2 days Fzd1  
Fzd4  
Wnt5b 
Kremen1 
Fz6 
 
 
Time point of 
downregulation 
Maxiumum 
decrease 1-5-fold  
Maxiumum 
decrease 5-10-fold 
Maxiumum 
decrease >10-fold 
0-6 hours Fzd5  
Dkk1  
Cyclin D1 
  
6 hours-2 days WNT10B    
>2 days    
Very Low expression Not detected 
LEF1 
Fz8 
Fz10 
KREMEN2 
WNT3 
WNT4 
WNT7B 
WNT9B 
WNT11 
Rspo2 
WNT1 
WNT2 
WNT2B 
WNT3A 
WNT6 
WNT8A 
WNT8B 
WNT9A 
WNT10A 
WNT16 
Rspo3 
 
Table 2: Summary of Taq Man qRT-PCR analysis of gene expression regulation. 
Genes were ordered arranged according to their time point and extend of up/downregulation. 
 
 
3.3 Influence on cellular processes by novel GSK-3β inhibitors 
 
Wnt/β-catenin signaling is connected to several processes such as differentiation, 
proliferation, cell death, cell polarity, self- renewal and morphogenic movements (Moon 
et al, 2004). As it had been successfully demonstrated that AB199 acts as a GSK-3β 
inhibitor and possesses the ability to activate and support endogenous Wnt signaling 
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during differentiation, the next step was to investigate how this manipulation affects 
proliferation and differentiation of hNPCs. 
3.3.1 Novel GSK-3β inhibitors inhibit cell proliferation of hNPCs 
 
To investigate whether or not cell proliferation was influenced by the presence of GSK-3β 
inhibitors, cells were seeded at a defined number and proliferated for 24h. Then GSK-3β 
inhibitors were added to the medium and cells were cultivated under proliferation 
conditions. Every 24h, fresh medium containing drugs was provided and the cell number 
was counted (2.2.1.5). 
 
Figure 21: Cell proliferation of hNPCS is decelerated after treatment with GSK-3β inhibitors.  
(A) Growth curve of treated hNPCs. Cells were seeded at a defined cell density and were 
cultivated in the presence of DMSO, SB-216763 or AB199. The cell number was determined every 
24h. (B) Doubling time of hNPCs. Doubling times were calculated with the data from growth 
curves in Figure 21A. The conditioning of proliferating cells with SB-216763 or AB199 resulted in a 
significant increase of the cell doubling time. Concentrations were 3µM for SB-216763 (SB21) and 
AB199. After 72h of treatment, SB-216763 and AB199 significantly reduced the cell proliferation. 
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Data represent mean ± SEM (N = 4, each done in triplicates). Values were significantly different 
between drug treated cells and DMSO treated control cells at *p <0.05 and **p <0.01. 
 
hNPCs showed an exponential growth curve and a doubling time of 19.8 ± 0.6h was 
calculated. In contrast, treatment of the cells with SB-216763 and AB199 increased the 
cell doubling time significantly to 24.4 ± 0.7h and 26.5 ± 0.9h, respectively (Fig. 21a). The 
numbers of SB-216763 and AB199 treated cells were significantly reduced after 72 h 
compared to the number of DMSO treated control cells (Fig. 21b). This effect seemed not 
be cytotoxic as cell viability was not influenced (data not shown).  
 
As the conditioning of hNPCs with GSK-3β inhibitors lead to decreased cell proliferation 
the question arose whether these results are connected to the accumulation of β-catenin. 
Do substances which increase β-catenin accumulation also decelerate cell proliferation of 
hNPCs and maybe the other way around or is this a phenomenon which is specific to SB-
216763 and AB199? To verify this hypothesis, different small molecules which either 
increased or decreased β-catenin accumulation were chosen to evaluate their influence 
on cell proliferation. Substances that ameliorated β-catenin accumulation were: PDA228-
1, PDA 228-3 and e993-0255, substances that depleted β-catenin accumulation were: 
AB209, PDA167, g288-0012. 
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Figure 22: Relation between cell doubling time and β-catenin accumulation in hNPCs.  
(A) Growth curve of treated hNPCs. Cells were seeded at a defined cell density and were 
cultivated in the presence of DMSO and different small molecules. The cell number was 
determined every 24h. (B) Doubling time of hNPCs. Doubling times were calculated with the data 
from growth curves in Figure 22A. (C) Relation between cell doubling time and β-catenin 
accumulation. Data represent mean +/- SEM (N=4, each done in triplicates). Values were 
significantly different between drug treated and DMSO treated control cells at *p< 0.05 or 
**p<0.01. 
 
None of the tested substances seemed to affect cell proliferation as there was no 
significant difference in the cell number or in the cell doubling time (Fig. 22a and b). Only 
AB209 significantly decelerated cell proliferation and decreased the cell doubling time 
(Fig. 22a and b). AB209 is of high structural similarity to AB199. 
Fig 22c shows the relation between β-catenin accumulation and cell proliferation. No 
relation between β-catenin accumulation and cell proliferation was observed. 
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3.3.2 Neuronal differentiation of hNPCs is influenced by GSK-3β inhibition 
 
As it was demonstrated that proliferation of hNPCs is decelerated by GSK-3β inhibition, it 
was investigated how the inhibition of GSK-3β influences neuronal differentiation of 
hNPCs. 
First the gene expression of neuronal markers Tuj1 and Map2 were analyzed. hNPCs were 
differentiated for up to 4 days in the presence of either DMSO (control), SB-216763 or  
AB199. At defined time points, cells were harvested and total RNA was isolated (2.2.2.1). 
Isolated RNA was transcribed into cDNA and then analyzed with a customized TaqMan 
array (2.2.2.4).  
 
 
Figure 23: Expression of neuronal markers in differentiating hNPCs.  
hNPCs were differentiated up to 96h under the influence of 3µM SB-216763 (SB21), 3µM AB199 
or the equivalent amount of DMSO. Cells were harvested at indicated time points and mRNA level 
of Map2 and Tubb3 were detected by TaqMan quantitative real-time PCR. Values were 
normalized to GAPDH. Data were normalized to 0h differentiation and represent mean +/- SEM 
(N=4, each done in dublettes). Values were significantly different at *p< 0.05 or **p<0.01. 
 
Fig. 23 shows that the gene expression of both markers increases at the start of 
differentiation. After 24h, Map2 expression is already 6-fold compared to proliferating 
cells, whereas the expression of Tuj1 is a little delayed. Its expression starts to increase 
after 48h (3-fold compared to proliferating cells), and then 6-fold after 48h. This was 
expected as Map2 is described as an early marker of neuronal differentiation.  
The presence of GSK-3β inhibition to hNPC during differentiation had no effects on the 
expression of neuronal markes. Interestingly, the expression of Tuj1 was significantly 
reduced by SB-216763 compared to DMSO-control cells. AB199 had no influence on the 
expression of these two markers. 
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The next step was to investigate the influence of the GSK-3β inhibitors on neuronal 
differentiation on protein level. Therefore, hNPCs were differentiated for 3d in the 
presence of inhibitors, then immunocytochemically stained for βIII-tubulin and analyzed 
by flow cytometry (2.2.3.6). 
 
 
Figure 24: Influence of SB-216763 (SB-21) and AB199 on neuronal differentiation.  
hNPCs were differentiated in the presence of the compounds or DMSO. Expression of βIII-tubulin 
was determined by immunocytochemistry (insert A and B, scale bar indicates 20 µm) and 
quantified by flow cytometry (A and B). After 3 days of differentiation 2.0 ± 0.2% βIIItub+ cells 
were detected under control conditions. The treatment of cells with SB-216763 or AB199 resulted 
in an increase of βIIItub+ cells up to 3.2 ± 0.4 % and 3.7 ± 0.7%, respectively. Data represent mean 
± SEM (N = 6). *p<0.05. 
 
Proliferating cells expressed βIII-tubulin at a very low percentage (0.02%) which is most 
likely caused by spontaneous differentiation (Fig. 24c). Previous experiments have shown 
that the expression of βIII-tubulin in hNPCs peaked after 3d (Morgan et al, 2009).  In this 
study 2% βIIItub+ cells after 3d of differentiation were detected (Fig. 24c). This number 
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could be increased significantly by the addition of SB-216763 to 3.2% βIIItub+ cells. 
Conditioning of the cells with AB199 could even augment the effect caused by SB-216367, 
whereas 3.7% of the cells were positive for βIII-tubulin. This effect was significantly 
different to control cells, but not to SB-216763-treated cells. 
 
3.3.3 Different effects of GSK-3β inhibitors on apoptosis in hNPC 
 
As demonstrated, the treatment of the hNPCs with GSK-3β inhibitors results in an 
increase of βIII-tubulin+-cells. This raised the question whether this effect is based on an 
enlarged progenitor pool or if GSK-3β inhibitors act in a neuroprotective way. It has been 
described that GSK-3β may promote apoptosis (Bijur et al, 2001 und 2000). Inestrosa and 
co-workers demonstrated that in Alzheimer’s disease, the inhibition of GSK-3β by lithium 
and PKC activators obviate neuronal damage which is caused by Amyloidβ-toxicity (De 
Ferrari et al., 2003; Garrido et al., 2002). Thus, we wanted to know if early differentiation 
of hNPCs is connected to apoptosis and how this might be influenced by GSK-3β 
inhibitors. 
hNPCs were differentiated in the presence of GSK-3β inhibitors up to 12h. Cells were 
harvested every 3h and then stained with Annexin and PI (Propidiumiodide) (2.2.3.7). 
Annexin binds to phosphatidylserine, which is translocated during apoptosis from the 
inner side of the membrane to the outer side. PI can enter the cells through the disrupted 
membrane of dead cells and binds to DNA. One can distinguish between alive. (Annexin-
/PI-), early apoptotic (Annexin+/PI-), and late apoptotic or dead cells (Annexin+/PI+). 
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Figure 25: Apoptosis during early differentiation of hNPCs is influenced differently by GSK-3β 
inhibitors.  
Cells were cultured under differentiation conditions up to 12h in the presence of 3µM SB-216763 
(SB21), AB199 or the equivalent amount of DMSO. Then cells were harvested, stained with 
Annexin/PI and measured by flow cytometry. SB-216763 reduced significantly the number of early 
apoptotic cells. Data represent mean +/- SEM (N=3-10). Values were significantly different at *p< 
0.05 or **p<0.01. 
 
hNPCs showed no increase of early apoptotic cells after differentiation started, the 
number of late apoptotic cells decreased from 1.2% in proliferating cells to 0.9% after 12h 
of differentiation (Fig. 25b). SB-216763 significantly reduced the number of Annexin+/PI- 
cells after 6h from 7.4% to 3.5%, whereas AB199 did not imitate this effect (7.6% 
Annexin+/PI- cells) (Fig. 25d). After 9h, the number of early apoptotic cells was still 
significantly lower in SB-216763 cells than in AB199-treated cells. The number of late 
apoptotic cells was not influenced by GSK-3β inhibitors.  
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4  Discussion 
 
Human neural progenitor cells offer great potential to study proliferation and 
differentiation. An immortalized cell line has the advantage of a “never-ending source” 
and of high standardization. 
A plethora of studies have shown that Wnt/β-catenin signaling is involved in neural 
progenitor proliferation and differentiation in the murine or rat system (Castelo-Branco et 
al., 2003; Hirsch et al., 2007; Shimizu et al., 2008; Kunke et al., 2009). Artificial stimulation 
of Wnt/β-catenin signaling by GSK-3β inhibition would enable us to study the influence of 
this signaling pathway in human neural progenitor cells. Another use for GSK-3β inhibitors 
is the investigation of any disease which is linked to a malfunction of GSK-3β. 
Therefore, we wanted to develop a novel screening system to find new GSK-3β inhibitors 
and then evaluate their effect in hNPCs. 
 
 
4.1 GSK-3 inhibition and Wnt signaling in hNPC 
 
Previous data have shown that hNPCs respond to Wnt signals, either by blocking Wnt/β-
catenin signaling by treatment with DKK1 (Ahn et al., 2008) or activation by stimulation 
with Wnt-3a (Soen et al., 2006 Hübner et al., 2010). But the effect of the inhibition of 
GSK-3β on the activation of the Wnt/β-catenin signaling in hNPCs remains unclear.  
ReNcell VM have been shown to be capable of activating Wnt/β-catenin signaling by 
overexpression of a stabilized form of β-catenin. Thus, this cell line is suitable to study the 
influences of GSK-3β inhibition on Wnt/β-catenin signaling on hNPC and its outcome on 
cell proliferation and differentiation. 
 
4.1.1 GSK-3 inhibition and activation of Wnt cascade in hNPCs 
 
It is widely described that NPCs respond to GSK-3β inhibition with a β-catenin 
accumulation as β-catenin is one of the key substrates of GSK-3β. Thus, it is an often used 
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as an indirect read-out for GSK-3β inhibition (Adachi et al., 2007; Maurer et al., 2007; Jung 
et al., 2008). 
Treatment of hNPCs with known GSK-3 inhibitors Kenpaullone and SB-216763 resulted in 
an up-regulation of β-catenin (Fig. 5). In addition, native differentiation also increased the 
amount of β-catenin, but this effect was more prominent in the presence of Kenpaullone 
and SB-216763, indicating that the differentiation process is connected to GSK-3β 
inhibition. To investigate whether new compounds, structurally similar to known GSK-3β 
inhibitors, could increase β-catenin accumulation, nearly 200 novel small molecules were 
tested regarding their ability to accumulate β-catenin. Most of them had a high structural 
similarity to the known GSK-3β inhibitor SB-216763, whereas others included other 
structures that have been shown to be biologically active. Substances were provided by 
the Leibniz-Institute for Catalysis (LIKAT) and any analyses regarding structure and 
corresponding biological activity were performed by LIKAT. Several substances showed a 
β-catenin accumulation in the same range than known GSK-3β-inhibitors, but the first hit, 
namely AB199, was selected to investigate the influence of GSK-3β inhibition on Wnt/β-
catenin pathway in hNPC and its influence on hNPC proliferation and differentiation. 
AB199 enhanced β-catenin accumulation in the same range as Kenpaullone (Fig. 6). It was 
of interest whether or not structural modification of this 3-(4-Fluorophenylethylamino)-1-
methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione could even improve this effect or 
if there is any relation between structure and biological action. The effectiveness of 
AB199 could be ascribed to the amine moiety, which is an additional hydrogen bonding 
motif. In addition, it has been reported that biologically active substances often benefit 
from the presence of fluorine substituents due to improved metabolic stability, 
bioavailability and protein–ligand interactions of the fluorinated compounds (Hagmann, 
2008; Shah and Westwell, 2007). Thus, the substitution with one or more fluorine atoms 
(Woo et al., 2008; Memic and Spaller, 2008) and more specifically, the incorporation of 
the 4-fluorophenethylamine unit (Schenone et al., 2008; Saha et al., 2005) has led to an 
increased biological activity of small molecule therapeutics. 
Derivatization of AB199 resulted in no further improvement regarding β-catenin 
accumulation, indicating a specific relation between structure and action. 
The working concentration of an inhibitor is crucial for every experiment. Too high a 
concentration could cause unspecific binding and undefined side effects as well as 
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potential toxicity. On the other hand, a concentration which is too low could not be 
sufficient. SB-216763 and AB199 were tested in concentrations from 0.1-10µM regarding 
potential cytotoxicity in a cell metabolic activity, but none of the tested concentrations 
seemed to harm the cells. Previous experiments revealed a most prominent effective β-
catenin accumulation for SB-216763 with 3µM (Christian Lange, unpublished data). AB199 
showed an increasing β-catenin accumulation from 0.1-3µM with a maximum at 3µM but 
followed by a rapid decrease from 5µM to 10µM. An IC50 of 3.8µM was calculated but this 
specific kinetic offers only a very narrow therapeutic window. These effects cannot be 
explained with a potential cytotoxicity as this has been ruled out with experiments 
regarding metabolic activity (Fig. 14). Another possibility would be that β-catenin is also 
phosphorylated by other kinases such as CK1, PKA (protein kinase A), AKT or JNK2 
(Verheyen and Gottardi, 2009) and thus sufficiently primed for degradation. This idea is 
rather unlikely as the same bell-shaped dose-response curve was observed in an in vitro 
kinase activity assay, where a recombinant enzyme was used. The IC50 for SB-216763 was 
92nM, slightly higher than the given value in the literature (34nM, Coghlan et al., 2000). 
This difference could be explained by the fact that we used a luminometric detection 
system, whereas Coghlan and co-workers used radioactive detection. AB199 showed an 
even lower IC50 with 53nM. These data were be confirmed in a cell-based kinase-assay, 
where both substances at the same concentration inhibited GSK-3β in the same range. In 
both assays a bell-shape dose-respond curve was observed. This type of dose-response 
curve is well described for PKC (Govoni et al., 1992; Qiu et al., 1998; Moriguchi et al., 
2002), but these data are generated in cell-based assays, where other cellular 
components can be involved in enzyme regulation, like feedback-regulation of 
downstream components within signaling pathways. Involvement of other kinases or 
feedback-regulation could explain the downregulation of β-catenin accumulation in the 
presence of high inhibitor concentrations we observed, but not the re-activation of GSK-
3β in the in vitro kinase assay. As this assay is performed independent of any cellular 
influences, the reason for the bell-shaped dose-response relationship must be within the 
enzyme/activator kinetics itself. One possibility would be that AB199 agglutinates at a 
higher concentration and thus a binding to the ATP binding site would be impossible, 
therefore re-activating GSK-3β. Another explanation might be a change within the 
enzyme conformation after the binding of AB199. The conformation change could open 
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an additional ATP binding side which then re-activates GSK-3β. However, up to now, there 
is no information existing about GSK-3β as an allosteric enzyme. 
The combination of a constant concentration of SB-216763 with variable concentrations 
of AB199 did not enhance β-catenin accumulation. Again, it could be observed that higher 
concentration of GSK-3β inhibitors seemed to abolish the inhibitory effect of lower 
concentrations, indicating that high concentrations of AB199 are crucial for the activity of 
GSK-3β. 
 
As a consequence of the accumulation in the cytosol, β-catenin is translocated to the 
nucleus. The shuttling process has not been well described yet. Early suggestions that this 
process might be triggered by a nuclear location sequence (NLS) could not be verified as 
β-catenin does not possess a NLS (Fagotto et al., 1998). The translocation seems to be 
importin-independent but might involve direct interactions with nuclear pore proteins. 
Importin recognizes and binds NLS, thus enabling a protein to enter the nucleus 
(Henderson and Fagotto, 2002). This process could not be visualized in hNPCs, which is 
due to the growth pattern of ReNcell VM cells. ReNcell VM cells need to grow to 80% 
confluence to be differentiated and then form a dense network which makes it difficult to 
analyze single nuclei. Immunocytochemical stainings for β-catenin are rather diffuse (Fig. 
14).  To overcome this ST14A cells have been used to prove the accumulation of β-
catenin. ST14A cells are derived from rat striatum and display a flat morphology with 
grand nuclei. In addition, they have been used before to visualize nuclear β-catenin 
shuttling (Lange et al., 2006). Both, SB-216763 and AB199 triggered perinuclear β-catenin 
accumulation, indicating that both GSK-3 inhibitors promote the Wnt/β-catenin signaling 
pathway in hNPC. 
 
The intranuclear consequence of β-catenin translocation is the activation of TCF-
dependent transcription. This can be measured by a reportergene-assay, where a TCF/LEF 
reporter luciferase system is used. Transfected, proliferating cells showed no 
transcriptional activity, which is not unusual for NPCs (Lie et al., 2005; Wexler et al., 2009) 
but could also be below the detection limit. Previous data revealed that only 1.2% of 
proliferating ReNcell VM display TCF-dependent transcription, using a GFP-reporter 
construct (Jana Frahm, unpublished data). This could be a result of the short lifetime of 
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luciferase of only 2h. Downregulating of Wnt/β-catenin signaling during cell cycle phases 
is crucial for the proper development of other types of dividing progenitors (Aulehla et al., 
2003), but only a certain proportion of asynchronously proliferating cells will exhibit 
canonical activity which cannot be detected due the short lifetime of the luciferase. 
Surprisingly, differentiation as well as additional stimulation with GSK-3β inhibitors failed 
to induce TCF-activity (data not shown). This effect was be ruled out by co-expressing a 
stabilized form of β-catenin, S33Y, suggesting that a certain threshold of TCF/luciferase-
activity needs to be reached. The co-transfection successfully promoted TCF-activity and 
additional effects of GSK-3β could be distinguished (Fig. 16). TCF-activity increased under 
differentiation conditions over the time after an initial decrease after 6h. Inhibition of 
GSK-3β enhanced TCF-activity compared to control cells, whereas the kinetics seemed to 
be shifted. SB-216763-dependent effects reached a maximum after 18h, while AB199 
treated cells exhibited maximal TCF-activity after 24h. In general, TCF-activity seemed to 
be higher in AB199 treated cells than in SB-216763 treated cells. Several factors could be 
responsible for this. AB199 could also prime the nuclear shuttling of β-catenin or the 
kinetic of TCF-activity could be influenced by both substances in a different way. 
The fact that only a small population of hNPCs (6% after stimulation with stabilized β-
catenin) can activate TCF-mediated transcription is also described for other NPCs. Hirsch 
et al. (2007) report that treatment with SB-216763 or Wnt3a resulted in a TCF-activation 
in mNPCs of 14% and 8%, respectively. It is most likely that these effects are not cell line 
dependent or based on experimental problems rather than a physiological behavior, as 
the transcription efficiency of hNPCs is very high (higher than 90%) and any effects of 
secreted inhibitors have been excluded by the use of stabilized β-catenin. 
 
The nuclear translocation and the induction of TCF-activity are followed by the 
transcription by Wnt specific target genes. To this purpose, different target genes were 
analyzed regarding their transcriptional activity as a consequence by GSK-3β inhibition, 
namely Axin2, LEF1, c-Myc, Kremen 1 and 2, RSPO 2 and 3, Dkk1 and CCDN1, but only the 
expression of Axin2, Kremen 1, c-Myc, Dkk1 and CCDN1 could be detected in hNPC. Axin2 
has been described as a negative feedback regulator of Wnt signaling (Jho et al., 2002). 
Dkk1 inhibits Wnt/β-catenin signaling and was observed as a Wnt target gene in cancer 
cells (Niida et al., 2004). CCDN1 is a regulator of the cell cycle and is communicated as 
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Wnt target gene (Shtutman et al., 1999). C-Myc is the cellular homologue of the viral v-
Myc; the expression of the proto-oncogene can be induced by Wnt signaling (He et al., 
1998). 
In the hNPCs used in this study the start of differentiation upregulated the expression of 
Axin2 and Kremen 1 (Fig. 20a and e) with maximum expression after 96h. The expression 
of c-Myc was reduced slightly by the induction of differentiation but then also increased. 
In contrast to this, c-Myc, CCDN1 and Dkk1 expression were downregulated with the start 
of differentiation (Fig. 20b and d). This was expected as these genes are known to 
promote cell proliferation and conditions are now changed to differentiation conditions 
lacking growth factors. These findings correspond with the fact that the expression of 
these genes can be induced by FGF and EGF (Kurz et al., 2003; Corbetta et al., 2007). 
Interestingly, Axin2 expression was increased up to 30-fold compared to proliferating cells 
whereas the other genes responded with expression changes with only up to 5-fold. This 
corresponds with the finding that Axin2 contains 8 TCF/LEF binding site consensus 
sequences in its enhancer region and can be activated in various tissues (Jho et al., 2002). 
The main interest of these experiments was to find out whether or not the treatment of 
hNPC with GSK-3 inhibitors manipulates the expression of Wnt target genes. The 
expression of Kremen1 and Dkk1 was not influenced by the presence of small molecules. 
C-Myc and CCDN1 showed some slight increase in gene expression in the presence of SB-
216763 but not with AB199. This effect was not constant over the time. Only Axin2 
responded with a steady increase in gene expression to the presence of GSK-3β inhibitor 
SB-216763. But here, as well as for CCDN1 and c-Myc, this effect could not be observed 
for AB199. These data are on the same line as  the findings of Hirsch and colleagues 
(2007). They analyzed murine NPC and found that only a few of described Wnt target 
genes respond to stimulation of the Wnt/β-catenin pathway by the inhibition of GSK-3β, 
namely Axin2, Nkd1 (Naked 1) and TCF1. Expressions of other Wnt target genes could be 
detected, but were not influenced by GSK-3β inhibition. The authors also spotted an 
increased expression of LEF1 by SB-216763 which we could not detect at all. In contrast to 
this, an enhanced expression of CCDN1 by SB-216763 was observed whereas Hirsch et al. 
monitored no difference. This could be due to differences within the cell line origin. 
Interestingly, the novel GSK-3β inhibitor did not influence the expression of Wnt target 
genes, whereas the upstream processes, namely GSK-3β inhibition, β-catenin 
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accumulation, translocation and TCF-activity, were manipulated in the same range as in 
the presence of SB-216763. 
 
The expression of several components of the Wnt/β-catenin pathway was analyzed by 
TaqMan array. It was of interest whether or not differentiation of hNPCs influenced the 
expression of Wnt receptors and ligands and if this could be manipulated by GSK-3β 
inhibitors. A difference in expression of any upstream components of GSK-3β by its 
inhibition would suggest a positive or negative feedback loop. 
Within the expression of Wnt-related receptors, an endogenous expression of several 
receptors was monitored which changed at the start of differentiation. Several 
publications describe that NPCs express a manifold pattern of Wnt receptors (Rawal et al., 
2006; Ahn et al., 2008; Wexler et al., 2009). The expression of the co-receptor Ror2 
caught our attention, as it was marginal detectable under proliferation conditions but 
displayed a tremendous increase of expression after 24h of differentiation. The role of 
Ror2 is cell-type and ligand specific as it can bind Wnts and thus increasing or inhibiting 
Wnt/β-catenin signaling (Mikels and Nusse 2006; Li et al., 2008). Its increased expression 
during differentiation can be explained by its role in modulating neurite growth, their 
branching pattern and synaptic formation (Paganoni and Ferreira, 2005; Paganoni et al., 
2010).  
In addition, a few Wnt ligands could be detected, namely Wnt 5a, 5b, 7a and 10b. Wnt 5a 
is described as an activator of the Wnt/Ca2+-pathway (Slusarski et al., 1997), but it has 
also been shown that it can activate the Wnt/β-catenin dependent pathway in murine 
NPCs (Yu et al., 2005). Both Wnt 5a and 5b trigger proliferation and differentiation of 
chondrocytes, whereas only Wnt 5a has been demonstrated to support dopaminergic 
differentiation (Castelo-Branco et al., 2006; Anderson et al., 2008). The upregulation of 
these genes together with previous findings that ReNcell VM are capable to differentiate 
into dopaminergic neurons (Donato et al., 2007; Morgan et al., 2009, Ortinau et al., 2010) 
may suggest that the expression of Wnt 5a is connected to dopaminergic differentiation 
in hNPCs. Together with the upregulation of Ryk, another role for Wnt 5a could be axonal 
outgrowth during differentiation, as this has been described as a consequence of Wnt 5a 
binding to a Ryk receptor (Li et al., 2009). 
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Wnt 7a is expressed in various NPCs. Beside in hNPC ReNcell VM cells, it has been found 
in neonatal mouse NPCs (Hirsch et al., 2007), in cells of the human neural progenitor cell 
line HB1.F3 (Ahn et al., 2008), E.11.5-E13.5 mouse NPCs (Rawal et al., 2006) and in rat 
adult hippocampal progenitors (Wexler et al., 2009). However, its impact is discussed 
controversially as it is reported to either promote (Hirabayashi et al., 2004) or to obviate 
neuronal differentiation (Viti et al., 2003). Combined with Fzd7, it might be responsible 
for the predominantly glial-differentiation of ReNcell VM cells, as it has been shown to be 
expressed in glial population (Rawal et al., 2006). 
Beside native differentiation, gene expression of Wnt receptors and ligands was analyzed 
in the presence of GSK-3β inhibitors. Neither the expression of Wnt receptors nor the 
expression of Wnt ligands were significantly influenced by SB-216763 or AB199. These 
findings are in contrast to the data of Maurer and co-workers (2007) as they report that 
the treatment of rat hippocampal NPCs with SB-216763 resulted in an upregulation of 
Wnt 5a expression and a downregulation of Wnt 7a expression. In ReNcell VM cells a 
decrease of Wnt 5a expression after 72h by SB-216763 was detected, but in general SB-
216763 and AB199 seemed to have no effect on the expression of Wnt ligands or 
receptors. The difference to the data from Maurer could be explained with the different 
origin of the cells. The hypothesis that GSK-3β inhibition might manipulate the expression 
of Wnt ligands or receptors and therefore indicate a positive or negative feedback loop 
could not be verified in hNPCs. 
 
In conclusion, these data suggest that Wnt/β-catenin plays a pivotal role during the 
differentiation process of hNPCs which can be influenced GSK-3β inhibition. The next step 
was to investigate the impact of GSK-3β inhibitors on hNPCs proliferation and 
differentiation. 
 
4.1.2 Influence of GSK-3 inhibition on proliferation and differentiation of hNPCs 
 
The outcome of GSK-3β-inhibition of NPCs fate seems to depend mainly on cell origin and 
stage. In general, murine NPCs derived from early embryonic stages respond with 
enhanced proliferation to GSK-3β inhibition whereas NPCs obtained from later embryonic 
stages show an increased differentiation. 
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The hNPCs used in this study displayed a doubling time of 19.8h, which is fast compared 
to other NPCs, mainly of murine origin, which have doubling time of 4-7 days (Doetsch et 
al., 1999; Imura et al., 2003; Hirsch et al, 2007). Treatment of hNPCs resulted in a 
deceleration of cell proliferation and an increase of cell doubling time, 24.4h for SB-26763 
and 25.7h for AB199, respectively. These effects are controversially described in the 
literature. Hirsch and co-workers observed no effect of GSK-3β inhibition by SB-216763 
on proliferation of murine NPCs derived from the neonatal cortex. In contrast, murine 
NPCs isolated from the subventricular zone showed an enhanced proliferation as a 
consequence of GSK-3β inhibition by R3303544, which is structurally very similar to SB-
216763. The same effect of SB-216763 could be observed in murine NPCs derived from 
the telencephalon (Shimizu et al., 2008). GSK-3β inhibition has been also investigated in 
tumor cell lines. The size of colon tumors formed out of SW-480 cells could be reduced by 
treatment with SB-216763 or AR-A014418, another GSK-3β inhibitor (Shakoori et al., 
2007). Mazor and colleagues demonstrated that cell proliferation in prostate cancer cells 
is also decreased in the presence of SB-216763 (2004). They explain these results with 
their findings that GSK-3β is required for androgyn receptor (AR) transcriptional activity, 
which is a mediator for prostate cell growth. Therefore it is most likely that this 
explanation does not apply to hNPCs. It is more likely that resemblance of effects of GSK-
3 inhibition in tumor cells and the used hNPC cell line ReNcell VM could be a result of the 
immortalization of ReNcell VM cells with the proto-oncogene v-Myc, as this protein is also 
described as a target substrate of GSK-3β (Pulverer et al., 1994; Sears et al., 2000). C-Myc 
is phosphorylated by GSK-3β and therefore primed for degradation, by this process, cell 
proliferation can be inhibited. The cell cycle regulator Cyclin D1 has also been reported as 
target substrate of GSK-3β and is phosphorylated by the kinase as well and by this process 
prepared for degradation (Diehl et al., 1998). But as inhibition of GSK-3 would lead to a 
stabilization of these cell proliferation regulators, it is also improbable that these 
incidents are responsible for the reduced cell proliferation of hNPCs in the presence of 
GSK-3β inhibitors. Therefore the question arose whether the monitored effects depended 
on GSK-3β itself or if they were based on the activation of Wnt/β-catenin signaling. If 
substances that promote β-catenin accumulation diminish cell proliferation, then 
substances that do not influence or even suppress β-catenin accumulation should 
acclerate cell proliferation. Beside SB-216763 and AB199, none of the substance that 
Discussion  63 
 
enhanced β-catenin accumulation decelerated cell proliferation and the other way 
around. Quite the contrary, one small molecule that depleted β-catenin accumulation 
also significantly downregulated cell proliferation of hNPCs (Fig. 22c). Overexpression of 
stabilized β-catenin could not imitate this effect (Rayk Hübner, unpublished data), 
indicating that a downregulation of hNPCs proliferation is independent of β-catenin 
accumulation. ReNcell VM cells are characterized by a very low doubling time, thus it 
could be impossible to even further accelerate cell proliferation. Additional experiments 
independent of this work together with the here presented data support the idea the 
GSK-3β-mediated inhibition of cell proliferation is independent of Wnt/β-catenin 
signaling, but is probably caused by an interaction of GSK-3β and Notch signaling. This 
interaction is part of a different PhD thesis and was therefore not further investigated 
within this work. 
Some studies propose that there are different pools of GSK-3β, an Axin-bound GSK-3β 
that is responsible for β-catenin degradation and another pool of free GSK-3β which 
interacts with other pathways, such as PI3K or Notch (Ng et al., 2009; Wu and Pan, 2009). 
Inoki and co-workers (2006) present that GSK-3β regulates the TSC2- (tuberous sclerosis 
complex2) mTOR (mammalian target of rapamycin) pathway in the presence of Wnt, but 
apart from β-catenin. As this pathway is associated with the regulation of cell growth, it 
might explain why GSK-3β inhibition reduces hNPCs proliferation in a way independent 
from of β-catenin. 
 
Treatment of hNPCs with GSK-3β inhibitors resulted in a significant increase of βIII-tubulin 
positive cells. This has been observed with other GSK-3β inhibitors in other NPCs from 
later developmental stages, too. Castelo-Branco and co-workers (2004) treated 
progenitors from the rat ventral midbrain with KP and I3M and reported an increase in 
neurons as well as dopaminergic neurons. Maurer and colleagues (2007) demonstrated 
that GSK-3β inhibition via SB-216763 in rat hippocampal NPCs results in enhanced 
neuronal differentiation. They concluded that this increase is a result from the enhanced 
transcriptional activation of β-catenin dependent target genes. This theory does not apply 
to hNPCs, as the upregulation of Wnt-5a and downregulation of Wnt-7a expression by 
GSK-3β inhibition was not confirmed in hNPCs. 
Discussion  64 
 
In contrast, NPCs from early developmental stages show an increased proliferation and a 
decrease in neuronal differentiation when treated with GSK-3β inhibitors (Adachi et al., 
2007; Shimizu et al., 2008). Several other studies describe that activation of Wnt/β-
catenin pathway by Wnt3a promotes neuronal differentiation of murine NPCs from later 
stages but not from early, proliferating stages (Hirabayashi et al., 2004; Israsena et al., 
2004; Muroyama et al., 2004; Viti et al., 2003). 
But is this increase of βIII-tubulin positive cells based on a direct influence of GSK-3β 
inhibition-mediated activation of Wnt/β-catenin signaling, an enhancement of 
proliferation and thus enlarging of the neural progenitor pool or a neuroprotective effect 
of GSK-3β inhibition? The proneural genes Neurogenin 1 and 2 (Ngn1 and Ngn2) show an 
enhanced expression in the presence of stabilized β-catenin (Hirabayashi et al., 2004; 
Israsena et al., 2005). This would indicate a direct influence of Wnt/β-catenin on 
neurogenesis in mNPCs. In contrast, Hirsch et al. (2007) could not demonstrate a 
connection between cells that express the neuronal marker βIII-tubulin and cells that 
show TCF-activity. The increase of proliferation as a consequence of the activation of 
Wnt/β-catenin signaling, i.e. an extension of the neural progenitor pool would be another 
possibility, as Wnt signaling promotes proliferation of neural precursors from the rat 
hippocampus (Li et al., 2005). But this does not seem to apply to hNPCs of theReNcell VM 
cell line, as activation of Wnt/β-catenin signaling by Wnt3a resulted in a slight decrease in 
proliferation whereas overexpression of a stabilized form of β-catenin had no effect (Rayk 
Hübner, unpublished data). In addition, GSK-3β inhibition actually downregulated cell 
proliferation. 
 
Neurogenesis is tightly connected to apoptosis, as nearly half of the neuronal progenitor 
pool undergoes apoptosis caused by neuronal network formation processes and synaptic 
selection processes (Burek and Oppenheim, 1999). The Wnt/β-catenin pathway plays a 
crucial role for apoptotic processes during neuronal development. Wnt-mediated 
inhibition of c-myc-triggered cytochrome c-release is described to be anti-apoptotic (You 
et al., 2002; Kanei-Ishii et al., 2004). Other data suggest that β-catenin stabilization causes 
massive apoptotic cell death in the murine neural crest (Hasegawa et al., 2002). GSK-3β is 
linked to either pro- or anti-apopotic processes. On the one hand, it can directly 
phosphorylate Bax, a co-factor of the tumorsupressor protein p53, thus activating the 
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mitochondrial, intrinsic apoptotic signaling pathway. On the other hand, GSK-3β can 
promote the extrinsic apoptotic-signaling pathway by inhibiting caspase-8 (Beurel and 
Jope, 2006). 
Induction of differentiation resulted in a slight increase of early-apoptotic cells. This effect 
was constant over the first 12h of apoptosis. Interestingly, SB-216763 reduced the 
number of Annexin+/PI- negative cells during early differentiation, whereas AB199 could 
not achieve the same effect. SB-216763 has been shown to protect cerebellar granule 
neurons and sensory ganglionic neurons from cell death induced by either trophic factor 
withdrawal or PI 3-kinase inhibition (Cross et al., 2001). PI3K is a key enzyme of a cell 
survival pathway and upstream-regulator of GSK-3β (Facci et al., 2003). In addition, it has 
been shown that GSK-3β inhibition protects neurons from cell death by the stabilization 
of two GSK-3 targets, β-catenin and Tau (Cross et al., 2001), indicating that GSK-3β 
inhibition is a crucial tool for neuronal apoptosis. GSK-3β inhibition by SB-216763 has 
been demonstrated to block Bax and Caspase-3 activation as a consequence of the 
removal of growthfactors in murine NPCs (Eom et al., 2007). Maurer and co-workers 
(2007) identified GSK-3β as a key-regulator regarding differentiation and survival of rat 
NPCs. Treatment of rat NPCs with GSK-3β inhibitor SB-216763 resulted in an upregulation 
of neuronal differentiation as well as reduced apoptosis, evidencing that the increase of 
neurons is based on enhanced cell survival during differentiation.  As in this study a 
downregulation of early apoptotic processes by inhibiting GSK-3β with SB-216763 during 
differentiation of hNPCs was observed, these data suggest, too, that GSK-3β inhibition 
results in an increasing cell survival during differentiation, thus expanding the number of 
neurons. Surprisingly, AB199 did not counterfeit this effect, indicating that there might be 
a different, not neuro-protective effect for the increase in βIII-tubulin cells. 
 
 
4.2 Development of a multi-screening system for novel GSK-3 inhibitors 
 
Multi-level screenings have gained more and more interest within the last years, whereas 
the targets vary. They are either focussed on specific targets, like pathway 
inhibitors/activators, or on the cell fate, disregarding the cell processes they manipulate. 
Most screenings include a broad, rather unspecific screening, followed by several, more 
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and more specific, assays. Borowiak et al. (2009) screened for small molecules that 
promote endodermal differentiation by using a fluorescent Sox17-dsRed-reporter. Sox17 
is a marker and effector specific for endodermal differentiation. A secondary screen 
evaluated the function of potential hit substances to promote formation of homogeneous 
clusters of Sox-17-dsRed+ epithelial cells in different mouse cell lines. As a last step, they 
identified two hit substances as modulators of Smad2-phosphorylation, indicating the 
substances induce Nodal synthesis and secretion. Nodal is a member of the TGF-family 
and involved in cell differentiation. Another screening for substances inducing Sox17-
expression revealed a substance, namely stauprimide, that primes ESC for ectoderm, 
endoderm and mesoderm differentiation by interacting with NME-3, a cMyc interacting 
transcription factor (Zhu et al., 2009). The emergence of iPSC in 2006 (Takahashi and 
Yamanaka) opened another field for novel small molecules that could either substitute 
one or more of the oncogenic transcription factors or promote the low transcription 
efficiencies. The known GSK-3β inhibitor Kenpaullone has been identified out of 50,000 
substances to substitute the transcription factor Klf4 (Lyssiotis et al., 2009). They used a 
Nanog-Luciferase reporter strain as a read-out for iPSC formation, as Nanog is an 
important factor for maintaining the undifferentiated state and is inactivated in somatic 
lineages. Interestingly the replacing effect of Kenpaullone is independent of its ability to 
inhibit GSK-3β, as other, more specific inhibitors, could not mimic this effect. 
Most screenings systems used to find Wnt modulating agents search for Wnt/β-catenin 
signaling inhibitors, as Wnt signaling is often constitutively active in several tumors 
(preferential in the intestine), which are mostly due to the loss of  function of APC, 
Axin1/2 or stabilizing mutations of β-catenin (Clevers, 2006). GSK-3β is an interesting 
pharmalogical target, as it is not only involved in cancer but also in Alzheimer’s disease 
(Phiel et al, 2003), bipolar disorders (Gould, 2006) or diabetes (Cohen and Goedert, 2004). 
Different studies have shown that the activation of Wnt/β-catenin in NPCs from later 
developmental stages promotes neuronal differentiation (Hirabayashi et al., 2004; 
Muroyama et al., 2004; Hirsch et al., 2007; Hübner et al., 2010). This could be also 
demonstrated when NPCs were treated with GSK-3β inhibitors (Castelo-Branco et al., 
2004; Maurer et al., 2007). Hence, one aim of this study was to develop a multi-level 
screening system to identify novel GSK-3β inhibitors that elevate neuronal differentiation 
in hNPCs. The initial screening should cover a broad range, thus an ELISA for β-catenin 
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was chosen. β-catenin is suitable as a read-out parameter for GSK-3β inhibition, as its 
accumulation is a consequence of GSK-3 inhibition. An ELISA can be performed in 96-well 
format and is easy to standardize. The next step should cover the activation of the Wnt/β-
catenin pathway as well as the proof that the β-catenin accumulation  is due to direct 
GSK-3β inhibition. An in-vitro GSK-3 binding assay with a recombinant enzyme is a clear 
evidence for a GSK-3β inhibitor, as any cellular components that could cause side effects 
are excluded. This system could be performed with luminometric detection (Baki et al., 
2007), which is of great advantage in comparison to any radioactive detection system. 
The calculated IC50 for SB-216763 as GSK-3β inhibitor of 92nM is in the same range of the 
given literature value of 34nM (Coghlan et al., 2000). The differences could be caused by 
the different detection systems, as Baki et al. (2007) also reported slight differences 
between the radioactive literature IC50, radioactive in-house measurements and 
luminometrically performed assays. As this assay can be also performed in 96-well or 
smaller format, which would be an interesting approach for a high-throughput screening. 
A downstream consequence of GSK-3β inhibition and cytosolic β-catenin accumulation is 
the nuclear translocation. The nuclear β-catenin accumulation is very hard to visualize 
and detect in the used cell line, which is caused by the dense growth pattern of ReNcell 
VM cells. In contrast the TCF-dependent transcriptional activity as well is described as a 
read-out for GSK-3β inhibition and therefore the activation of Wnt/β-catenin signaling 
(Liu et al., 2005; Zhang et al., 2007; Chuang et al., 2010; Ewan et al., 2010). Here, an 
increase of TCF-activity in the presence of GSK-3β inhibitors compared to control cells 
was shown, though the co-transfection of a stabilizing form of β-catenin is necessary. 
Although ReNcell VM cells can be transfected at a very high efficiency (higher than 90%), 
a stable transfection would improve this assay as transfection of this cell line is connected 
to a high variance. The expression of Wnt/β-catenin related target genes revealed not to 
be suitable as a read-out for GSK-3β inhibitors as we could not detect any differences in 
gene expression mediated by GSK-3β inhibition. Only SB-216763 could influence Axin2 
expression but not AB199. This is on the same line as the data of Hirsch and-co-workers 
(2007) as they report that only a few genes respond to GSK-3β inhibition. Not only the 
expression of Wnt target genes but also the expression of Wnt ligands or Wnt receptor 
was not affected by GSK-3β inhibition. The best targets for evaluating the effects of β-
catenin accumulation modulating substances in hNPCs would thus be firstly, an in vitro 
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kinase assay to test whether the increase in β-catenin accumulation is therefore based on 
GSK-3β inhibition or not and secondly, to measure the TCF-mediated transcription 
activity, as this is a well-described assay to examine the activity of Wnt/β-catenin 
signaling.  
Of final interest would be if the new identified GSK-3β inhibitors can improve neuronal 
differentiation in hNPCs. The detection of neuronal markers via flow cytometry enables a 
much higher throughput than immunocytochemical staining combined with manual 
counting. The detected cells positive for neuronal markers are comparable in both 
systems (data not shown). The influence of GSK-3β inhibitors on cell proliferation or 
apoptosis are of interest regarding the mechanism of action but not relevant for a 
screening system. 
In conclusion, the following screening system for the development and evaluation novel 
GSK-3β inhibitors is proposed: 
 
 
 
Figure 26: Final multi-screening approach for novel GSK-3β-inhibitors. 
 
The primary screen evaluates the accumulation of β-catenin in the cell as a consequence 
of potential GSK-3β inhibition. The secondary screening step investigates on the one hand 
the direct inhibition of GSK-3β by novel small molecules; on the other hand, the TCF-
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dependent transcription activity is analyzed as a downstream target of GSK-3β inhibition 
and Wnt/β-catenin signaling. The third screening step covers the impact of GSK-3β 
inhibition on neuronal differentiation of hNPCs. 
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5 Summary 
 
Wnt signaling is crucial for the developing CNS, wherein GSK-3β is the key enzyme. It has 
been shown that Wnt/β-catenin signaling can promote neurogenesis in NPCs from later 
developmental stages. As the activation of Wnt/β-catenin cannot only be induced by 
binding of a Wnt ligand, but also by the inhibition of GSK-3β, small molecule inhibitors for 
GSK-3β are of great interest. In addition to this, GSK-3β is an interesting pharmacological 
target as it is involved in various diseases, such as diabetes, cancer, bipolar disorders or 
Alzheimer’s disease.  
The human neural progenitor cell line ReNcell VM can differentiate into astrocytes, 
oligodendrocytes and functional neurons and has been also shown to be appropriate for 
Wnt signaling studies.  
The aim of this study was to develop a multi-level-screening system for novel GSK-3β 
inhibitors and to analyze their impact on proliferation and differentiation on hNPCs. 
This study has demonstrated for the first time that β-catenin is present in hNPCs and can 
be accumulated by the treatment of hNPCs with GSK-3β inhibitors. Accumulation of β-
catenin is subsequently followed by nuclear translocation and activation of TCF-
dependent activity. The expression of different Wnt target genes as well as gene 
expression of Wnt receptors and ligands could be proven. Conditioning of hNPC with GSK-
3β inhibitors did not implicate changes in the expression profile of Wnt components, thus 
indicating that the inhibition of GSK-3β causes no feedback loop by activating any 
upstream components of the Wnt/β-catenin pathway. The known GSK-3β inhibitor SB-
216763 as well as the newly discovered GSK-3β inhibitor AB199 triggered these processes 
with the same efficiency, whereas AB199 displayed a lower IC50 value for GSK-3β 
inhibition than SB-216763, indicating a higher specificity. 
Cellular consequences of GSK-3β inhibition were a reduced cell proliferation, whereas an 
enhanced neuronal differentiation was observed. In the case of SB-216763, this effect 
was most likely based on a neuro-protective effect, as SB-216763 reduced the number of 
early apoptotic cells during early differentiation. As AB199 did not show the same anti-
apoptotic effects, its mechanism of action remains unclear, a possible explanation would 
be an increase in the pool of NPCs. 
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The results obtained propose the following read-outs for a screening approach for novel 
GSK-3β inhibitors: 
1. Accumulation of β-catenin 
2. a) Inhibition of GSK-3β 
b) Activation of TCF-dependent activity 
3.   Influence on neuronal differentiation 
 
This study also revealed some cytotoxic small molecules. Their impact on the proliferation 
and viability of tumor cells and the mechanisms of action are currently investigated in an 
independent PhD thesis. 
 
 
Literature  72 
 
6 Literature 
 
Aberle H, Schwartz H, Kemler R (1996) Cadherin-catenin complex: protein interactions 
and their implications for cadherin function. J Cell Biochem 61: 514-523. 
Adachi K, Mirzadeh Z, Sakaguchi M, Yamashita T, Nikolcheva T, Gotoh Y, Peltz G, Gong L, 
Kawase T, Alvarez-Buylla A, Okano H, Sawamoto K (2007) Beta-catenin signaling promotes 
proliferation of progenitor cells in the adult mouse subventricular zone. Stem Cells 25: 
2827-2836. 
Ahn SM, Byun K, Kim D, Lee K, Yoo JS, Kim SU, Jho EH, Simpson RJ, Lee B (2008) Olig2-
induced neural stem cell differentiation involves downregulation of Wnt signaling and 
induction of Dickkopf-1 expression. PLoS One 3: e3917. 
Akiyama Y, Honmou O, Kato T, Uede T, Hashi K, Kocsis JD (2001) Transplantation of clonal 
neural precursor cells derived from adult human brain establishes functional peripheral 
myelin in the rat spinal cord. Exp Neurol 167: 27-39. 
Andersson ER, Prakash N, Cajanek L, Minina E, Bryja V, Bryjova L, Yamaguchi TP, Hall AC, 
Wurst W, Arenas E (2008) Wnt5a regulates ventral midbrain morphogenesis and the 
development of A9-A10 dopaminergic cells in vivo. PLoS One 3: e3517. 
Arce L, Yokoyama NN, Waterman ML (2006) Diversity of LEF/TCF action in development 
and disease. Oncogene 25: 7492-7504. 
Arsenijevic Y, Villemure JG, Brunet JF, Bloch JJ, Deglon N, Kostic C, Zurn A, Aebischer P 
(2001) Isolation of multipotent neural precursors residing in the cortex of the adult 
human brain. Exp Neurol 170: 48-62. 
Aulehla A, Wehrle C, Brand-Saberi B, Kemler R, Gossler A, Kanzler B, Herrmann BG (2003) 
Wnt3a plays a major role in the segmentation clock controlling somitogenesis. Dev Cell 4: 
395-406. 
Bain J, McLauchlan H, Elliott M, Cohen P (2003) The specificities of protein kinase 
inhibitors: an update. Biochem J 371: 199-204. 
Baki A, Bielik A, Molnar L, Szendrei G, Keseru GM (2007) A high throughput luminescent 
assay for glycogen synthase kinase-3beta inhibitors. Assay Drug Dev Technol 5: 75-83. 
Beurel E, Jope RS (2006) The paradoxical pro- and anti-apoptotic actions of GSK3 in the 
intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 79: 173-189. 
Bijur GN, De Sarno P, Jope RS (2000) Glycogen synthase kinase-3beta facilitates 
staurosporine- and heat shock-induced apoptosis. Protection by lithium. J Biol Chem 275: 
7583-7590. 
Bijur GN, Jope RS (2001) Proapoptotic stimuli induce nuclear accumulation of glycogen 
synthase kinase-3 beta. J Biol Chem 276: 37436-37442. 
Literature  73 
 
Borowiak M, Maehr R, Chen S, Chen AE, Tang W, Fox JL, Schreiber SL, Melton DA (2009) 
Small molecules efficiently direct endodermal differentiation of mouse and human 
embryonic stem cells. Cell Stem Cell 4: 348-358. 
Bryja V, Andersson ER, Schambony A, Esner M, Bryjova L, Biris KK, Hall AC, Kraft B, 
Cajanek L, Yamaguchi TP, Buckingham M, Arenas E (2009) The extracellular domain of 
Lrp5/6 inhibits noncanonical Wnt signaling in vivo. Mol Biol Cell 20: 924-936. 
Bultje RS, Castaneda-Castellanos DR, Jan LY, Jan YN, Kriegstein AR, Shi SH (2009) 
Mammalian Par3 regulates progenitor cell asymmetric division via notch signaling in the 
developing neocortex. Neuron 63: 189-202. 
Cadigan KM, Liu YI (2006) Wnt signaling: complexity at the surface. J Cell Sci 119: 395-402. 
Cai J, Weiss ML, Rao MS (2004) In search of "stemness". Exp Hematol 32: 585-598. 
Castano Z, Gordon-Weeks PR, Kypta RM (2010) The neuron-specific isoform of glycogen 
synthase kinase-3beta is required for axon growth. J Neurochem 113: 117-130. 
Castelo-Branco G, Wagner J, Rodriguez FJ, Kele J, Sousa K, Rawal N, Pasolli HA, Fuchs E, 
Kitajewski J, Arenas E (2003) Differential regulation of midbrain dopaminergic neuron 
development by Wnt-1, Wnt-3a, and Wnt-5a. Proc Natl Acad Sci U S A 100: 12747-12752. 
Castelo-Branco G, Rawal N, Arenas E (2004) GSK-3beta inhibition/beta-catenin 
stabilization in ventral midbrain precursors increases differentiation into dopamine 
neurons. J Cell Sci 117: 5731-5737. 
Castelo-Branco G, Sousa KM, Bryja V, Pinto L, Wagner J, Arenas E (2006) Ventral midbrain 
glia express region-specific transcription factors and regulate dopaminergic neurogenesis 
through Wnt-5a secretion. Mol Cell Neurosci 31: 251-262. 
Chamorro MN, Schwartz DR, Vonica A, Brivanlou AH, Cho KR, Varmus HE (2005) FGF-20 
and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer 
and development. EMBO J 24: 73-84. 
Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W, Sun L, Yang X, Wang Y, Zhang Y, Shang Y (2008) 
The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J 
Biol Chem 283: 17969-17978. 
Chenn A, Walsh CA (2003) Increased neuronal production, enlarged forebrains and 
cytoarchitectural distortions in beta-catenin overexpressing transgenic mice. Cereb 
Cortex 13: 599-606. 
Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, Tsai TH, Chou SH, Chien CS, Ku HH, Lo JF (2008) 
Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral 
squamous cell carcinoma. Clin Cancer Res 14: 4085-4095. 
Chuang KA, Lieu CH, Tsai WJ, Wu MH, Chen YC, Liao JF, Wang CC, Kuo YC (2010) 
Evaluation of anti-Wnt/beta-catenin signaling agents by pGL4-TOP transfected stable cells 
with a luciferase reporter system. Braz J Med Biol Res 43: 931-941. 
Literature  74 
 
Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell 127: 469-
480. 
Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, Rausch OL, Murphy 
GJ, Carter PS, Roxbee CL, Mills D, Brown MJ, Haigh D, Ward RW, Smith DG, Murray KJ, 
Reith AD, Holder JC (2000) Selective small molecule inhibitors of glycogen synthase 
kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 7: 793-803. 
Cohen P, Goedert M (2004) GSK3 inhibitors: development and therapeutic potential. Nat 
Rev Drug Discov 3: 479-487. 
Cole A, Frame S, Cohen P (2004) Further evidence that the tyrosine phosphorylation of 
glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. 
Biochem J 377: 249-255. 
Corbetta S, Eller-Vainicher C, Vicentini L, Lania A, Mantovani G, Beck-Peccoz P, Spada A 
(2007) Modulation of cyclin D1 expression in human tumoral parathyroid cells: effects of 
growth factors and calcium sensing receptor activation. Cancer Lett 255: 34-41. 
Cross DA, Culbert AA, Chalmers KA, Facci L, Skaper SD, Reith AD (2001) Selective small-
molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from 
death. J Neurochem 77: 94-102. 
Cselenyi CS, Jernigan KK, Tahinci E, Thorne CA, Lee LA, Lee E (2008) LRP6 transduces a 
canonical Wnt signal independently of Axin degradation by inhibiting GSK3's 
phosphorylation of beta-catenin. Proc Natl Acad Sci U S A 105: 8032-8037. 
Daniels DL, Weis WI (2005) Beta-catenin directly displaces Groucho/TLE repressors from 
Tcf/Lef in Wnt-mediated transcription activation. Nat Struct Mol Biol 12: 364-371. 
Davidson G, Wu W, Shen J, Bilic J, Fenger U, Stannek P, Glinka A, Niehrs C (2005) Casein 
kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction. 
Nature 438: 867-872. 
De Ferrari GV, Chacon MA, Barria MI, Garrido JL, Godoy JA, Olivares G, Reyes AE, Alvarez 
A, Bronfman M, Inestrosa NC (2003) Activation of Wnt signaling rescues 
neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol 
Psychiatry 8: 195-208. 
Dejmek J, Safholm A, Kamp NC, Andersson T, Leandersson K (2006) Wnt-5a/Ca2+-induced 
NFAT activity is counteracted by Wnt-5a/Yes-Cdc42-casein kinase 1alpha signaling in 
human mammary epithelial cells. Mol Cell Biol 26: 6024-6036. 
Diehl JA, Cheng M, Roussel MF, Sherr CJ (1998) Glycogen synthase kinase-3beta regulates 
cyclin D1 proteolysis and subcellular localization. Genes Dev 12: 3499-3511. 
Doetsch F, Caille I, Lim DA, Garcia-Verdugo JM, Alvarez-Buylla A (1999) Subventricular 
zone astrocytes are neural stem cells in the adult mammalian brain. Cell 97: 703-716. 
Literature  75 
 
Donato R, Miljan EA, Hines SJ, Aouabdi S, Pollock K, Patel S, Edwards FA, Sinden JD (2007) 
Differential development of neuronal physiological responsiveness in two human neural 
stem cell lines. BMC Neurosci 8: 36. 
Eom TY, Roth KA, Jope RS (2007) Neural precursor cells are protected from apoptosis 
induced by trophic factor withdrawal or genotoxic stress by inhibitors of glycogen 
synthase kinase 3. J Biol Chem 282: 22856-22864. 
Ewan K, Pajak B, Stubbs M, Todd H, Barbeau O, Quevedo C, Botfield H, Young R, Ruddle R, 
Samuel L, Battersby A, Raynaud F, Allen N, Wilson S, Latinkic B, Workman P, McDonald E, 
Blagg J, Aherne W, Dale T (2010) A useful approach to identify novel small-molecule 
inhibitors of Wnt-dependent transcription. Cancer Res 70: 5963-5973. 
Facci L, Stevens DA, Skaper SD (2003) Glycogen synthase kinase-3 inhibitors protect 
central neurons against excitotoxicity. Neuroreport 14: 1467-1470. 
Fagotto F, Gluck U, Gumbiner BM (1998) Nuclear localization signal-independent and 
importin/karyopherin-independent nuclear import of beta-catenin. Curr Biol 8: 181-190. 
Flax JD, Aurora S, Yang C, Simonin C, Wills AM, Billinghurst LL, Jendoubi M, Sidman RL, 
Wolfe JH, Kim SU, Snyder EY (1998) Engraftable human neural stem cells respond to 
developmental cues, replace neurons, and express foreign genes. Nat Biotechnol 16: 
1033-1039. 
Forde JE, Dale TC (2007) Glycogen synthase kinase 3: a key regulator of cellular fate. Cell 
Mol Life Sci 64: 1930-1944. 
Garrido JL, Godoy JA, Alvarez A, Bronfman M, Inestrosa NC (2002) Protein kinase C 
inhibits amyloid beta peptide neurotoxicity by acting on members of the Wnt pathway. 
FASEB J 16: 1982-1984. 
Gould TD, Picchini AM, Einat H, Manji HK (2006) Targeting glycogen synthase kinase-3 in 
the CNS: implications for the development of new treatments for mood disorders. Curr 
Drug Targets 7: 1399-1409. 
Govoni S, Lucchi L, Battaini F, Trabucchi M (1992) Protein kinase C increase in rat brain 
cortical membranes may be promoted by cognition enhancing drugs. Life Sci 50: L125-
L128. 
Habas R, Kato Y, He X (2001) Wnt/Frizzled activation of Rho regulates vertebrate 
gastrulation and requires a novel Formin homology protein Daam1. Cell 107: 843-854. 
Hagmann WK (2008) The many roles for fluorine in medicinal chemistry. J Med Chem 51: 
4359-4369. 
Hall AC, Lucas FR, Salinas PC (2000) Axonal remodeling and synaptic differentiation in the 
cerebellum is regulated by WNT-7a signaling. Cell 100: 525-535. 
Hasegawa S, Sato T, Akazawa H, Okada H, Maeno A, Ito M, Sugitani Y, Shibata H, Miyazaki 
JJ, Katsuki M, Yamauchi Y, Yamamura KK, Katamine S, Noda T (2002) Apoptosis in neural 
Literature  76 
 
crest cells by functional loss of APC tumor suppressor gene. Proc Natl Acad Sci U S A 99: 
297-302. 
He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, 
Kinzler KW (1998) Identification of c-MYC as a target of the APC pathway. Science 281: 
1509-1512. 
He X, Semenov M, Tamai K, Zeng X (2004) LDL receptor-related proteins 5 and 6 in 
Wnt/beta-catenin signaling: arrows point the way. Development 131: 1663-1677. 
Henderson BR, Fagotto F (2002) The ins and outs of APC and beta-catenin nuclear 
transport. EMBO Rep 3: 834-839. 
Hipper A, Isenberg G (2000) Cyclic mechanical strain decreases the DNA synthesis of 
vascular smooth muscle cells. Pflugers Arch 440: 19-27. 
Hirabayashi Y, Itoh Y, Tabata H, Nakajima K, Akiyama T, Masuyama N, Gotoh Y (2004) The 
Wnt/beta-catenin pathway directs neuronal differentiation of cortical neural precursor 
cells. Development 131: 2791-2801. 
Hirabayashi Y, Gotoh Y (2005) Stage-dependent fate determination of neural precursor 
cells in mouse forebrain. Neurosci Res 51: 331-336. 
Hirsch C, Campano LM, Wohrle S, Hecht A (2007) Canonical Wnt signaling transiently 
stimulates proliferation and enhances neurogenesis in neonatal neural progenitor 
cultures. Exp Cell Res 313: 572-587. 
Hoppler S, Kavanagh CL (2007) Wnt signalling: variety at the core. J Cell Sci 120: 385-393. 
Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, Nusse R, 
Dawid IB, Nathans J (1999) A new secreted protein that binds to Wnt proteins and inhibits 
their activities. Nature 398: 431-436. 
Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, Chen S, Muhlestein W, Melton 
DA (2008) Induction of pluripotent stem cells from primary human fibroblasts with only 
Oct4 and Sox2. Nat Biotechnol 26: 1269-1275. 
Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, Melton DA (2008) 
Induction of pluripotent stem cells by defined factors is greatly improved by small-
molecule compounds. Nat Biotechnol 26: 795-797. 
Hubner R, Schmole AC, Liedmann A, Frech MJ, Rolfs A, Luo J (2010) Differentiation of 
human neural progenitor cells regulated by Wnt-3a. Biochem Biophys Res Commun 400: 
358-362. 
Hughes K, Nikolakaki E, Plyte SE, Totty NF, Woodgett JR (1993) Modulation of the 
glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J 12: 803-808. 
Hur EM, Zhou FQ (2010) GSK3 signalling in neural development. Nat Rev Neurosci 11: 
539-551. 
Literature  77 
 
Imura T, Kornblum HI, Sofroniew MV (2003) The predominant neural stem cell isolated 
from postnatal and adult forebrain but not early embryonic forebrain expresses GFAP. J 
Neurosci 23: 2824-2832. 
Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, 
Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL (2006) TSC2 
integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 
to regulate cell growth. Cell 126: 955-968. 
Israsena N, Hu M, Fu W, Kan L, Kessler JA (2004) The presence of FGF2 signaling 
determines whether beta-catenin exerts effects on proliferation or neuronal 
differentiation of neural stem cells. Dev Biol 268: 220-231. 
Iwata T, Hevner RF (2009) Fibroblast growth factor signaling in development of the 
cerebral cortex. Dev Growth Differ 51: 299-323. 
Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F (2002) Wnt/beta-catenin/Tcf 
signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. 
Mol Cell Biol 22: 1172-1183. 
Jiang H, Guo W, Liang X, Rao Y (2005) Both the establishment and the maintenance of 
neuronal polarity require active mechanisms: critical roles of GSK-3beta and its upstream 
regulators. Cell 120: 123-135. 
Joksimovic M, Yun BA, Kittappa R, Anderegg AM, Chang WW, Taketo MM, McKay RD, 
Awatramani RB (2009) Wnt antagonism of Shh facilitates midbrain floor plate 
neurogenesis. Nat Neurosci 12: 125-131. 
Jung GA, Yoon JY, Moon BS, Yang DH, Kim HY, Lee SH, Bryja V, Arenas E, Choi KY (2008) 
Valproic acid induces differentiation and inhibition of proliferation in neural progenitor 
cells via the beta-catenin-Ras-ERK-p21Cip/WAF1 pathway. BMC Cell Biol 9: 66. 
Kanei-Ishii C, Ninomiya-Tsuji J, Tanikawa J, Nomura T, Ishitani T, Kishida S, Kokura K, 
Kurahashi T, Ichikawa-Iwata E, Kim Y, Matsumoto K, Ishii S (2004) Wnt-1 signal induces 
phosphorylation and degradation of c-Myb protein via TAK1, HIPK2, and NLK. Genes Dev 
18: 816-829. 
Kazanskaya O, Glinka A, del BB, I, Stannek P, Niehrs C, Wu W (2004) R-Spondin2 is a 
secreted activator of Wnt/beta-catenin signaling and is required for Xenopus myogenesis. 
Dev Cell 7: 525-534. 
Khan Z, Vijayakumar S, de la Torre TV, Rotolo S, Bafico A (2007) Analysis of endogenous 
LRP6 function reveals a novel feedback mechanism by which Wnt negatively regulates its 
receptor. Mol Cell Biol 27: 7291-7301. 
Kim DS, Kim JY, Kang M, Cho MS, Kim DW (2007) Derivation of functional dopamine 
neurons from embryonic stem cells. Cell Transplant 16: 117-123. 
Literature  78 
 
Kim JB, Zaehres H, Wu G, Gentile L, Ko K, Sebastiano V, Arauzo-Bravo MJ, Ruau D, Han 
DW, Zenke M, Scholer HR (2008) Pluripotent stem cells induced from adult neural stem 
cells by reprogramming with two factors. Nature 454: 646-650. 
Kim SU (2004) Human neural stem cells genetically modified for brain repair in 
neurological disorders. Neuropathology 24: 159-171. 
Kim WY, Wang X, Wu Y, Doble BW, Patel S, Woodgett JR, Snider WD (2009) GSK-3 is a 
master regulator of neural progenitor homeostasis. Nat Neurosci 12: 1390-1397. 
Kimelman D, Xu W (2006) beta-catenin destruction complex: insights and questions from 
a structural perspective. Oncogene 25: 7482-7491. 
Klaus A, Birchmeier W (2008) Wnt signalling and its impact on development and cancer. 
Nat Rev Cancer 8: 387-398. 
Klein PS, Melton DA (1996) A molecular mechanism for the effect of lithium on 
development. Proc Natl Acad Sci U S A 93: 8455-8459. 
Klipp E, Liebermeister W (2006) Mathematical modeling of intracellular signaling 
pathways. BMC Neurosci 7 Suppl 1: S10. 
Knoepfler PS (2008) Why myc? An unexpected ingredient in the stem cell cocktail. Cell 
Stem Cell 2: 18-21. 
Korbling M, Estrov Z, Champlin R (2003) Adult stem cells and tissue repair. Bone Marrow 
Transplant 32 Suppl 1: S23-S24. 
Kuhl M, Sheldahl LC, Park M, Miller JR, Moon RT (2000) The Wnt/Ca2+ pathway: a new 
vertebrate Wnt signaling pathway takes shape. Trends Genet 16: 279-283. 
Kunke D, Bryja V, Mygland L, Arenas E, Krauss S (2009) Inhibition of canonical Wnt 
signaling promotes gliogenesis in P0-NSCs. Biochem Biophys Res Commun 386: 628-633. 
Kurz DJ, Hong Y, Trivier E, Huang HL, Decary S, Zang GH, Luscher TF, Erusalimsky JD (2003) 
Fibroblast growth factor-2, but not vascular endothelial growth factor, upregulates 
telomerase activity in human endothelial cells. Arterioscler Thromb Vasc Biol 23: 748-754. 
Lange C, Mix E, Rateitschak K, Rolfs A (2006) Wnt signal pathways and neural stem cell 
differentiation. Neurodegener Dis 3: 76-86. 
Lange C, Mix E, Frahm J, Glass A, Muller J, Schmitt O, Schmole AC, Klemm K, Ortinau S, 
Hubner R, Frech MJ, Wree A, Rolfs A (2010) Small molecule GSK-3 inhibitors increase 
neurogenesis of human neural progenitor cells. Neurosci Lett. 
Leost M, Schultz C, Link A, Wu YZ, Biernat J, Mandelkow EM, Bibb JA, Snyder GL, 
Greengard P, Zaharevitz DW, Gussio R, Senderowicz AM, Sausville EA, Kunick C, Meijer L 
(2000) Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-
dependent kinase 5/p25. Eur J Biochem 267: 5983-5994. 
Literature  79 
 
Leung T, Manser E, Tan L, Lim L (1995) A novel serine/threonine kinase binding the Ras-
related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem 
270: 29051-29054. 
Li C, Chen H, Hu L, Xing Y, Sasaki T, Villosis MF, Li J, Nishita M, Minami Y, Minoo P (2008) 
Ror2 modulates the canonical Wnt signaling in lung epithelial cells through cooperation 
with Fzd2. BMC Mol Biol 9: 11. 
Li L, Hutchins BI, Kalil K (2009) Wnt5a induces simultaneous cortical axon outgrowth and 
repulsive axon guidance through distinct signaling mechanisms. J Neurosci 29: 5873-5883. 
Lie DC, Colamarino SA, Song HJ, Desire L, Mira H, Consiglio A, Lein ES, Jessberger S, 
Lansford H, Dearie AR, Gage FH (2005) Wnt signalling regulates adult hippocampal 
neurogenesis. Nature 437: 1370-1375. 
Ling ZD, Potter ED, Lipton JW, Carvey PM (1998) Differentiation of mesencephalic 
progenitor cells into dopaminergic neurons by cytokines. Exp Neurol 149: 411-423. 
Liu J, Wu X, Mitchell B, Kintner C, Ding S, Schultz PG (2005) A small-molecule agonist of 
the Wnt signaling pathway. Angew Chem Int Ed Engl 44: 1987-1990. 
Loebel DA, Watson CM, De Young RA, Tam PP (2003) Lineage choice and differentiation in 
mouse embryos and embryonic stem cells. Dev Biol 264: 1-14. 
Logan CY, Nusse R (2004) The Wnt signaling pathway in development and disease. Annu 
Rev Cell Dev Biol 20: 781-810. 
Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon HK, Brundin P (2002) Effect of mutant 
alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J Biol 
Chem 277: 38884-38894. 
Lu W, Yamamoto V, Ortega B, Baltimore D (2004) Mammalian Ryk is a Wnt coreceptor 
required for stimulation of neurite outgrowth. Cell 119: 97-108. 
Lyssiotis CA, Foreman RK, Staerk J, Garcia M, Mathur D, Markoulaki S, Hanna J, Lairson LL, 
Charette BD, Bouchez LC, Bollong M, Kunick C, Brinker A, Cho CY, Schultz PG, Jaenisch R 
(2009) Reprogramming of murine fibroblasts to induced pluripotent stem cells with 
chemical complementation of Klf4. Proc Natl Acad Sci U S A 106: 8912-8917. 
Maccioni RB, Munoz JP, Barbeito L (2001) The molecular bases of Alzheimer's disease and 
other neurodegenerative disorders. Arch Med Res 32: 367-381. 
Machold R, Hayashi S, Rutlin M, Muzumdar MD, Nery S, Corbin JG, Gritli-Linde A, 
Dellovade T, Porter JA, Rubin LL, Dudek H, McMahon AP, Fishell G (2003) Sonic hedgehog 
is required for progenitor cell maintenance in telencephalic stem cell niches. Neuron 39: 
937-950. 
Mao Y, Ge X, Frank CL, Madison JM, Koehler AN, Doud MK, Tassa C, Berry EM, Soda T, 
Singh KK, Biechele T, Petryshen TL, Moon RT, Haggarty SJ, Tsai LH (2009) Disrupted in 
schizophrenia 1 regulates neuronal progenitor proliferation via modulation of 
GSK3beta/beta-catenin signaling. Cell 136: 1017-1031. 
Literature  80 
 
Martin-Rendon E, Watt SM (2003) Stem cell plasticity. Br J Haematol 122: 877-891. 
Maurer MH, Bromme JO, Feldmann RE, Jr., Jarve A, Sabouri F, Burgers HF, Schelshorn DW, 
Kruger C, Schneider A, Kuschinsky W (2007) Glycogen synthase kinase 3beta (GSK3beta) 
regulates differentiation and proliferation in neural stem cells from the rat subventricular 
zone. J Proteome Res 6: 1198-1208.  
Mazemondet O, Hübner R, Frahm J, Koczan D, Bader B, Weiss DG, Uhrmacher AM, Frech 
M, Rolfs A, Luo J (2010) Quantitative and kinetic profile of Wnt/β-catenin signaling 
components during human neural progenitor cell differentiation. Manuscript in 
preparation 
Mazor M, Kawano Y, Zhu H, Waxman J, Kypta RM (2004) Inhibition of glycogen synthase 
kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene 
23: 7882-7892. 
Medina A, Reintsch W, Steinbeisser H (2000) Xenopus frizzled 7 can act in canonical and 
non-canonical Wnt signaling pathways: implications on early patterning and 
morphogenesis. Mech Dev 92: 227-237. 
Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M, Ryan XP, 
Vonica CA, Brivanlou A, Dajani R, Crovace C, Tarricone C, Musacchio A, Roe SM, Pearl L, 
Greengard P (2003) GSK-3-selective inhibitors derived from Tyrian purple indirubins. 
Chem Biol 10: 1255-1266. 
Memic A, Spaller MR (2008) How do halogen substituents contribute to protein-binding 
interactions? A thermodynamic study of peptide ligands with diverse aryl halides. 
Chembiochem 9: 2793-2795. 
Mikels AJ, Nusse R (2006) Wnts as ligands: processing, secretion and reception. Oncogene 
25: 7461-7468. 
Moon RT, Kohn AD, De Ferrari GV, Kaykas A (2004) WNT and beta-catenin signalling: 
diseases and therapies. Nat Rev Genet 5: 691-701. 
Morgan PJ, Ortinau S, Frahm J, Kruger N, Rolfs A, Frech MJ (2009) Protection of neurons 
derived from human neural progenitor cells by veratridine. Neuroreport 20: 1225-1229. 
Moriguchi S, Watanabe S, Kita H, Nakanishi H (2002) Enhancement of N-methyl- D-
aspartate receptor-mediated excitatory postsynaptic potentials in the neostriatum after 
methamphetamine sensitization. An in vitro slice study. Exp Brain Res 144: 238-246. 
Mukai F, Ishiguro K, Sano Y, Fujita SC (2002) Alternative splicing isoform of tau protein 
kinase I/glycogen synthase kinase 3beta. J Neurochem 81: 1073-1083. 
Muroyama Y, Kondoh H, Takada S (2004) Wnt proteins promote neuronal differentiation 
in neural stem cell culture. Biochem Biophys Res Commun 313: 915-921. 
Ng SS, Mahmoudi T, Danenberg E, Bejaoui I, de Lau W, Korswagen HC, Schutte M, Clevers 
H (2009) Phosphatidylinositol 3-kinase signaling does not activate the wnt cascade. J Biol 
Chem 284: 35308-35313. 
Literature  81 
 
Niida A, Hiroko T, Kasai M, Furukawa Y, Nakamura Y, Suzuki Y, Sugano S, Akiyama T (2004) 
DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. 
Oncogene 23: 8520-8526. 
Ortinau S, Schmich J, Block S, Liedmann A, Jonas L, Weiss DG, Helm CA, Rolfs A, Frech MJ 
(2010) Effect of 3D-scaffold formation on differentiation and survival in human neural 
progenitor cells. Biomed Eng Online 9: 70. 
Paganoni S, Ferreira A (2005) Neurite extension in central neurons: a novel role for the 
receptor tyrosine kinases Ror1 and Ror2. J Cell Sci 118: 433-446. 
Paganoni S, Bernstein J, Ferreira A (2010) Ror1-Ror2 complexes modulate synapse 
formation in hippocampal neurons. Neuroscience 165: 1261-1274. 
Palma I, Pena RY, Contreras A, Ceballos-Reyes G, Coyote N, Erana L, Kofman-Alfaro S, 
Queipo G (2008) Participation of OCT3/4 and beta-catenin during dysgenetic gonadal 
malignant transformation. Cancer Lett 263: 204-211. 
Palmer TD, Schwartz PH, Taupin P, Kaspar B, Stein SA, Gage FH (2001) Cell culture. 
Progenitor cells from human brain after death. Nature 411: 42-43. 
Phiel CJ, Wilson CA, Lee VM, Klein PS (2003) GSK-3alpha regulates production of 
Alzheimer's disease amyloid-beta peptides. Nature 423: 435-439. 
Piao S, Lee SH, Kim H, Yum S, Stamos JL, Xu Y, Lee SJ, Lee J, Oh S, Han JK, Park BJ, Weis WI, 
Ha NC (2008) Direct inhibition of GSK3beta by the phosphorylated cytoplasmic domain of 
LRP6 in Wnt/beta-catenin signaling. PLoS One 3: e4046. 
Polychronopoulos P, Magiatis P, Skaltsounis AL, Myrianthopoulos V, Mikros E, Tarricone 
A, Musacchio A, Roe SM, Pearl L, Leost M, Greengard P, Meijer L (2004) Structural basis 
for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase 
kinase-3 and cyclin-dependent kinases. J Med Chem 47: 935-946. 
Popperl H, Schmidt C, Wilson V, Hume CR, Dodd J, Krumlauf R, Beddington RS (1997) 
Misexpression of Cwnt8C in the mouse induces an ectopic embryonic axis and causes a 
truncation of the anterior neuroectoderm. Development 124: 2997-3005. 
Potter ED, Ling ZD, Carvey PM (1999) Cytokine-induced conversion of mesencephalic-
derived progenitor cells into dopamine neurons. Cell Tissue Res 296: 235-246. 
Pulverer BJ, Fisher C, Vousden K, Littlewood T, Evan G, Woodgett JR (1994) Site-specific 
modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene 9: 
59-70. 
Qiu J, Lou LG, Huang XY, Lou SJ, Pei G, Chen YZ (1998) Nongenomic mechanisms of 
glucocorticoid inhibition of nicotine-induced calcium influx in PC12 cells: involvement of 
protein kinase C. Endocrinology 139: 5103-5108. 
Rawal N, Castelo-Branco G, Sousa KM, Kele J, Kobayashi K, Okano H, Arenas E (2006) 
Dynamic temporal and cell type-specific expression of Wnt signaling components in the 
developing midbrain. Exp Cell Res 312: 1626-1636. 
Literature  82 
 
Ridley AJ, Hall A (1992) The small GTP-binding protein rho regulates the assembly of focal 
adhesions and actin stress fibers in response to growth factors. Cell 70: 389-399. 
Ryder EF, Snyder EY, Cepko CL (1990) Establishment and characterization of multipotent 
neural cell lines using retrovirus vector-mediated oncogene transfer. J Neurobiol 21: 356-
375. 
Saha AK, Liu L, Simoneaux R, DeCorte B, Meyer C, Skrzat S, Breslin HJ, Kukla MJ, End DW 
(2005) Novel triazole based inhibitors of Ras farnesyl transferase. Bioorg Med Chem Lett 
15: 5407-5411. 
Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH (2004) Maintenance of 
pluripotency in human and mouse embryonic stem cells through activation of Wnt 
signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 10: 55-63. 
Schambony A, Wedlich D (2007) Wnt-5A/Ror2 regulate expression of XPAPC through an 
alternative noncanonical signaling pathway. Dev Cell 12: 779-792. 
Schenone S, Brullo C, Bruno O, Bondavalli F, Mosti L, Maga G, Crespan E, Carraro F, 
Manetti F, Tintori C, Botta M (2008) Synthesis, biological evaluation and docking studies 
of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines. Eur J Med Chem 43: 2665-2676. 
Schneider JW, Gao Z, Li S, Farooqi M, Tang TS, Bezprozvanny I, Frantz DE, Hsieh J (2008) 
Small-molecule activation of neuronal cell fate. Nat Chem Biol 4: 408-410. 
Schuldiner M, Eiges R, Eden A, Yanuka O, Itskovitz-Eldor J, Goldstein RS, Benvenisty N 
(2001) Induced neuronal differentiation of human embryonic stem cells. Brain Res 913: 
201-205. 
Schulte G, Bryja V, Rawal N, Castelo-Branco G, Sousa KM, Arenas E (2005) Purified Wnt-5a 
increases differentiation of midbrain dopaminergic cells and dishevelled phosphorylation. 
J Neurochem 92: 1550-1553. 
Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR (2000) Multiple Ras-dependent 
phosphorylation pathways regulate Myc protein stability. Genes Dev 14: 2501-2514. 
Shah P, Westwell AD (2007) The role of fluorine in medicinal chemistry. J Enzyme Inhib 
Med Chem 22: 527-540. 
Shakoori A, Mai W, Miyashita K, Yasumoto K, Takahashi Y, Ooi A, Kawakami K, Minamoto 
T (2007) Inhibition of GSK-3 beta activity attenuates proliferation of human colon cancer 
cells in rodents. Cancer Sci 98: 1388-1393. 
Sheldahl LC, Slusarski DC, Pandur P, Miller JR, Kuhl M, Moon RT (2003) Dishevelled 
activates Ca2+ flux, PKC, and CamKII in vertebrate embryos. J Cell Biol 161: 769-777. 
Shi Y, Do JT, Desponts C, Hahm HS, Scholer HR, Ding S (2008) A combined chemical and 
genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell 2: 
525-528. 
Literature  83 
 
Shimizu T, Kagawa T, Inoue T, Nonaka A, Takada S, Aburatani H, Taga T (2008) Stabilized 
beta-catenin functions through TCF/LEF proteins and the Notch/RBP-Jkappa complex to 
promote proliferation and suppress differentiation of neural precursor cells. Mol Cell Biol 
28: 7427-7441. 
Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben Ze'ev A (1999) 
The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 
96: 5522-5527. 
Slusarski DC, Yang-Snyder J, Busa WB, Moon RT (1997) Modulation of embryonic 
intracellular Ca2+ signaling by Wnt-5A. Dev Biol 182: 114-120. 
Soen Y, Mori A, Palmer TD, Brown PO (2006) Exploring the regulation of human neural 
precursor cell differentiation using arrays of signaling microenvironments. Mol Syst Biol 2: 
37. 
Stadeli R, Hoffmans R, Basler K (2006) Transcription under the control of nuclear 
Arm/beta-catenin. Curr Biol 16: R378-R385. 
Tahinci E, Thorne CA, Franklin JL, Salic A, Christian KM, Lee LA, Coffey RJ, Lee E (2007) Lrp6 
is required for convergent extension during Xenopus gastrulation. Development 134: 
4095-4106. 
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676. 
Tamai K, Zeng X, Liu C, Zhang X, Harada Y, Chang Z, He X (2004) A mechanism for Wnt 
coreceptor activation. Mol Cell 13: 149-156. 
Tang M, Villaescusa JC, Luo SX, Guitarte C, Lei S, Miyamoto Y, Taketo MM, Arenas E, 
Huang EJ (2010) Interactions of Wnt/beta-catenin signaling and sonic hedgehog regulate 
the neurogenesis of ventral midbrain dopamine neurons. J Neurosci 30: 9280-9291. 
Temple S, Alvarez-Buylla A (1999) Stem cells in the adult mammalian central nervous 
system. Curr Opin Neurobiol 9: 135-141. 
Tropepe V, Sibilia M, Ciruna BG, Rossant J, Wagner EF, van der KD (1999) Distinct neural 
stem cells proliferate in response to EGF and FGF in the developing mouse telencephalon. 
Dev Biol 208: 166-188. 
van Amerongen R, Mikels A, Nusse R (2008) Alternative wnt signaling is initiated by 
distinct receptors. Sci Signal 1: re9. 
Villa A, Navarro B, Martinez-Serrano A (2002) Genetic perpetuation of in vitro expanded 
human neural stem cells: cellular properties and therapeutic potential. Brain Res Bull 57: 
789-794. 
Viti J, Gulacsi A, Lillien L (2003) Wnt regulation of progenitor maturation in the cortex 
depends on Shh or fibroblast growth factor 2. J Neurosci 23: 5919-5927. 
Literature  84 
 
Vlad A, Rohrs S, Klein-Hitpass L, Muller O (2008) The first five years of the Wnt targetome. 
Cell Signal 20: 795-802. 
Wallingford JB, Habas R (2005) The developmental biology of Dishevelled: an enigmatic 
protein governing cell fate and cell polarity. Development 132: 4421-4436. 
Wei D, Kanai M, Huang S, Xie K (2006) Emerging role of KLF4 in human gastrointestinal 
cancer. Carcinogenesis 27: 23-31. 
Weissman IL (2000) Stem cells: units of development, units of regeneration, and units in 
evolution. Cell 100: 157-168. 
Wexler EM, Paucer A, Kornblum HI, Palmer TD, Geschwind DH (2009) Endogenous Wnt 
signaling maintains neural progenitor cell potency. Stem Cells 27: 1130-1141. 
Woo LW, Fischer DS, Sharland CM, Trusselle M, Foster PA, Chander SK, Di Fiore A, 
Supuran CT, De Simone G, Purohit A, Reed MJ, Potter BV (2008) Anticancer steroid 
sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro 
and in vivo activities, molecular modeling, and protein crystallography. Mol Cancer Ther 
7: 2435-2444. 
Wood-Kaczmar A, Kraus M, Ishiguro K, Philpott KL, Gordon-Weeks PR (2009) An 
alternatively spliced form of glycogen synthase kinase-3beta is targeted to growing 
neurites and growth cones. Mol Cell Neurosci 42: 184-194. 
Woodgett JR (1990) Molecular cloning and expression of glycogen synthase kinase-
3/factor A. EMBO J 9: 2431-2438. 
Wu D, Pan W (2010) GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem Sci 35: 
161-168. 
Wu G, Huang H, Garcia AJ, He X (2009) Inhibition of GSK3 phosphorylation of beta-catenin 
via phosphorylated PPPSPXS motifs of Wnt coreceptor LRP6. PLoS One 4: e4926. 
Wu X, Tu X, Joeng KS, Hilton MJ, Williams DA, Long F (2008) Rac1 activation controls 
nuclear localization of beta-catenin during canonical Wnt signaling. Cell 133: 340-353. 
Ying QL, Wray J, Nichols J, Batlle-Morera L, Doble B, Woodgett J, Cohen P, Smith A (2008) 
The ground state of embryonic stem cell self-renewal. Nature 453: 519-523. 
Yoon K, Gaiano N (2005) Notch signaling in the mammalian central nervous system: 
insights from mouse mutants. Nat Neurosci 8: 709-715. 
Yoshimura T, Kawano Y, Arimura N, Kawabata S, Kikuchi A, Kaibuchi K (2005) GSK-3beta 
regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 120: 137-149. 
You Z, Saims D, Chen S, Zhang Z, Guttridge DC, Guan KL, MacDougald OA, Brown AM, 
Evan G, Kitajewski J, Wang CY (2002) Wnt signaling promotes oncogenic transformation 
by inhibiting c-Myc-induced apoptosis. J Cell Biol 157: 429-440. 
Literature  85 
 
Yu JM, Kim JH, Song GS, Jung JS (2006) Increase in proliferation and differentiation of 
neural progenitor cells isolated from postnatal and adult mice brain by Wnt-3a and Wnt-
5a. Mol Cell Biochem 288: 17-28. 
Zechner D, Fujita Y, Hulsken J, Muller T, Walther I, Taketo MM, Crenshaw EB, III, 
Birchmeier W, Birchmeier C (2003) beta-Catenin signals regulate cell growth and the 
balance between progenitor cell expansion and differentiation in the nervous system. Dev 
Biol 258: 406-418. 
Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R, Okamura H, Woodgett J, He X (2005) A 
dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 438: 
873-877. 
Zhang Q, Major MB, Takanashi S, Camp ND, Nishiya N, Peters EC, Ginsberg MH, Jian X, 
Randazzo PA, Schultz PG, Moon RT, Ding S (2007) Small-molecule synergist of the 
Wnt/beta-catenin signaling pathway. Proc Natl Acad Sci U S A 104: 7444-7448. 
Zhang SC, Wernig M, Duncan ID, Brustle O, Thomson JA (2001) In vitro differentiation of 
transplantable neural precursors from human embryonic stem cells. Nat Biotechnol 19: 
1129-1133. 
Zhang Z, Hartmann H, Do VM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Sommer 
B, van de WM, Clevers H, Saftig P, De Strooper B, He X, Yankner BA (1998) Destabilization 
of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 395: 
698-702. 
Zhu S, Wurdak H, Wang J, Lyssiotis CA, Peters EC, Cho CY, Wu X, Schultz PG (2009) A small 
molecule primes embryonic stem cells for differentiation. Cell Stem Cell 4: 416-426. 
Appendix  V 
 
7 Appendix 
 
Acknowledgements 
 
Many people contributed to this work in various ways and I would like to thank them all: 
 
First of all Prof. Arndt Rolfs, for giving me the chance to work in his lab, his support and 
interest in my work 
 
Dr. Stefanie Ortinau and Dr. Moritz Frech shared my supervision during the 3 years of my 
PhD. Steffi, you were a great teacher in “How to write a paper”. Moritz, thanks for 
discussing my data, helping with figures “Corel ärgert mich schon wieder” and both for 
your overall support.  
 
The past and present AKos lab members: Andrea, Anne2, Annett, Caro, Christian, Ellen, 
Jan, Jana, Jiankai, Lea, Michi, Norman, Orianne, Peter, Ramona, Rayk, Steffen, Venkata 
and Xin 
Andrea is the Queen of flow cytometry, establishing so many different markers from what 
we all benefit. And for sharing sherbets;) 
Anne2 motivated me for our Friday-library-thesis-writing-session 
Christian “my” PhD student. Thank you for your great enthusiasm in this project 
Jana introduced me into the world of Wnts and the life as PhD student 
Jan for discussing data or experiments from the sight of a “non-Wnt fellow”. And of 
course for so many papers 
Peter for the proof-reading of my manuscripts 
Rayk has a question to every answer “ Ich hab da mal gelesen, dass…” or “Hast du mal 
folgendes probiert?” 
Ramona and Lea, our student assistants. Especially Lea, who took the load of me during 
the final stage of me thesis 
And finally Norman and Ellen, who are awesome technicians and the perfect lab 
managers. And beside this, great friends. Thank you! 
Appendix  VI 
 
 
The Leibniz-Institute for Catalysis, Prof. Matthias Beller and his group, for providing the 
small molecules. Especially Anahit Pews-Davtyan and Anne Brennführer for explaining the 
chemistry behind and writing papers. 
 
The research training group “dIEMoSIRIS” for giving the chance to get as an associated 
PhD student an insight in a, for me, total new field of science. 
 
Christiane, as my friend and PhD fellow sufferer. Even if we don’t meet that often or only 
in trains;) 
 
Tante Lore, for your brave proof-reading of my thesis. “Oh, ich verstehe, da fehlt kein 
Buchstabe, sondern Wnt scheint ein Eigenname zu sein”. 
 
Daniel, for your overall support and encouragement, 1200 km of train journeys on one 
weekend, bearing my steady frustration, weekends in the lab, Spitzen stecken. Thanks for 
everything! 
 
And finally my family, my parents Ursula und Helmut Schmöle and my sister Isabelle, for 
your support and encouragement during all periods of my life. Nonna, who would be very 
proud of me but left us shortly before the end. 
 
Thank you all! 
Appendix  VII 
 
Publications 
 
Published or Accepted Journal Publications 
 
Pews-Davtyan A., Tillack A., Schmöle A-C., Ortinau S., Frech MJ., Rolfs A., and Beller M. “A 
new facile synthesis of 3-amidoindole derivatives and their evaluation as potential GSK-3β 
inhibitors”, Org. Biomol. Chem, 2010, 8, 11-49-53 
 
Schmöle A-C., Brennführer A., Karapetyan G., Jaster R., Pews-Davytan A., Hübner R., 
Ortinau S., Beller M., Rolfs A., and Frech MJ. “Novel indolylmaleimide acts as GSK-3β 
inhibitor in human neural progenitor cells”, Bioorg. Med. Chem, 2010, 18, 6785–6795 
 
Hübner R, Schmöle A-C., Liedmann A, Frech MJ., Rolfs A., and Luo J. “Differentiation of 
human neural progenitor cells regulated by Wnt-3a” Biochem Biophys Res Commun, 
2010, 400, 358-362 
Lange C., Mix E., Frahm J., Glass Ä., Müller J., Schmidt O., Schmöle A-C., Klemm K., Ortinau 
S., Hübner R., Frech MJ., Wree A., and Rolfs A. “Small molecule GSK-3 inhibitors increase 
neurogenesis of human neural progenitor cells” Neuroscience Letters, in press, 2010 
 
 
Submitted  Publications 
 
 
Schmöle A-C., Rolfs A., and Frech MJ “Usage of Small Molecules in Stem Cell Research” 
submitted as invited review at Curr Pharm Biotech, 2010 
 
 
 
Abstract and Posters at Scientific Meetings 
 
Schmöle A-C., Pews-Dayvtan A., Brennführer A., Tillack A., Frahm J., Beller M., Rolfs A., 
und Ortinau S. “Glycogen Synthase Kinase-3β via the Accumulation of β-catenin in Human 
Neural Progenitor Cells“, 5th Stem Cell School for Regenerative Medicine, Berlin, 
Germany, 2008 
 
Schmöle A-C., Brennführer A., Pews-Dayvtan A., Tillack A., Frech MJ., Beller M., Rolfs A., 
und Ortinau S. “Inhibition of Glycogen Synthase Kinase-3β by novel small molecules 
activates Wnt signaling in Human Neural Progenitor Cells“, 6th Stem Cell School for 
Regenerative Medicine, Odense, Denmark, 2009 
 
Schmöle A-C., Brennführer A., Pews-Dayvtan A., Tillack A., Frech MJ., Beller M., Rolfs A., 
und Ortinau S. “New designed small molecules act as GSK-3 inhibitors in human neural 
progenitor cells”, Wnt Signaling in Development and Disease, Arolla, Switzerland, 2009 
 
Appendix  VIII 
 
Schmöle A-C., Brennführer A., Pews-Dayvtan A., Tillack A., Frech MJ., Beller M., Rolfs A., 
und Ortinau S. “New designed small molecules canonical as Wnt modulators in human 
neural progenitor cells”, 7th Stem Cell School in Regenerative Medicine, Prague, Czech 
Republic, 2009 
 
Karapetyan G., Schmöle A-C., Brennführer A., Jaster R., Pews-Davytan A., Hübner R., 
Ortinau S., Rolfs A., Frech MJ., und Beller M. “The Synthesis of Novel Indolylmaleimides 
and The Biological Activity as GSK-3β Inhibitors in Human Neural Progenitor Cells”, 
Gordon Research Conference-High Throughput Chemistry & Chemical Biology, Les 
Diablerets, Switzerland, 2010 
 
Schmöle A-C., Maciolek L., Brennführer A., Jaster R., Pews-Davtyan A., Beller M., Rolfs A. 
und Frech M. “Novel indolylmaleimide acts as GSK-3β inhibitor in human neural 
progenitor cells”, 8th Stem Cell School in Regenerative Medicine, Stockholm, Sweden, 
2010 
 
Hübner R., Schmöle A-C., Liedmann A., Frech MJ., Rolfs A. and Luo J. “Differentiation of 
human neural progenitor cells regulated by Wnt-3a”, 8th Stem Cell School in 
Regenerative Medicine, Stockholm, Sweden, 2010 
 
 
